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With the rapid evolution of antibiotic resistance, the need for more effective antibiotics 
is imminent. Bacterial membranes are an appealing target due to their accessibility and relatively 
conserved structures. Membrane targeting antibiotics, especially cationic antimicrobial peptides 
(CAMPs) such as host defense peptides, have been increasingly explored as novel antibiotics and 
tunable innate antimicrobials. The latter could be achieved by treatment with an antibiotic 
adjuvant: a compound that would increase the potency of host CAMPs without killing the 
bacteria on its own. Boosting the host’s own immune system with an adjuvant is beneficial over 
using antibiotics and would theoretically avoid triggering bacterial resistance. 
 One mechanism of bacterial resistance is increasing the cationic charge of the membrane. 
As CAMPs are electrostatically attracted to anionic bacterial membranes, making the membrane 
more cationic decreases that attraction, rendering CAMPs less effective. To target this resistance 
mechanism chemically, two antibiotic adjuvant strategies were explored as co-treatments with 
various CAMPs: membrane targeting peptides used to bind and block surface amines, and small 
molecules used to either acetylate surface amines or convert a cationic membrane phospholipid 
to an anionic phospholipid. 
Co-treatment of the Staphylococcus aureus (S. aureus) membrane targeting peptide KAM-
CT and various CAMPs increased S. aureus susceptibility to those CAMPs. Bacterial surface 
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acetylation using sulfo-NHS-acetate followed by CAMP treatment caused up to 10 times 
increased CAMP potency. Hydrazine and hydroxylamine were shown to cleave the lysine moiety 
from the lysyl-phosphatidylglycerol (Lys-PG) phospholipid to generate phosphatidylglycerol (PG) 
in liposome models. S. aureus was treated with a hydroxylamine-CAMP conjugate, but it showed 
decreased antibiotic activity compared to the CAMP alone. To better understand what was 
happening in the bacteria, a novel Lys-PG quantification protocol was created by fluorophore 
labeling Lys-PG and quantifying the labeled Lys-PG via normal phase high-performance liquid 
chromatography (NP-HPLC). 
 Cyclic peptides, such as KAM-CT, represent complex yet synthetically attainable moieties 
that could be used as novel antibiotics adjuvants. Expanding the repertoire of reversible covalent 
chemistries, especially those applied to peptide cyclization, is desirable due to the high potency 
and selectivity of such interactions. Herein, we also describe a novel reversible covalent 
chemistry between 2-formylphenylboronic acid (FPBA) and 2,3-diaminopropionic acid (Dap): the 
imidazolidino boronate (IzB) conjugate. It was found to be potent (Kd = 100 μM) and quickly 
reversible (t1 = ~6 sec) under physiological conditions. IzB formation was successfully employed 
as a peptide cyclization strategy as there was little interference from biologically relevant small 
molecules, except cysteine. Cysteine interference was utilized to create “smart” peptides that 
can linearize upon increasing cysteine concentrations via thiazolidino boronate (TzB) formation 
with the FPBA moiety in the peptide. Such “smart” peptides could be used as pH-responsive 
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CHAPTER 1: INTRODUCTION  
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1.1 General Antibiotic Resistance 
 Bacterial resistance is an ever-growing problem for which discovery of novel antibiotics is 
not occurring at the pace needed to keep up with clinical demand. Resistance towards antibiotics 
has emerged in as little as one year after the onset of clinical application. Notably, antibiotic 
discovery has slowed significantly since the end of the “Golden Age of Antibiotics” in the 1960s 
where natural products were isolated from culturable soil-dwelling bacteria and screened for 
antimicrobial activity, leading to identification of the major types of antibiotics (Figure 1-1).1 
Once those resources were exhausted, novel antibiotics were innovated by synthetically altering 
the existing natural products to induce increased potency, generating second generation 
antibiotics. Altering natural products is synthetically challenging as most compounds are 
structurally complex, such as vancomycin. However, the lag in antibiotic discovery that has 
resulted allowed bacteria to gain widespread resistance. 
 
 
Figure 1-1: Year of antibiotic clinical use (top) and clinical antibiotic resistance observed (bottom). 
Adapted from Clatworthy, A. E.; Pierson, E.; Hung, D. T. Nat Chem Biol 2007, 3 (9), 541–548. 
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Although antibiotic resistance was inevitable because bacteria evolve, it was exacerbated 
by a variety of factors: non-specific bacterial resistance mechanisms, including efflux pump 
upregulation to export antibiotics2; limited mechanisms of action, allowing for resistance to 
entire classes of antibiotics1; and horizontal gene transfer spreading resistance genes between 
species, creating multi-drug resistant bacteria.3 
In efforts to decrease the appearance of resistance and maintain clinical efficacy, 
membrane targeting antibiotics have become increasingly popular. The bacterial membrane is 
an appealing target because it is easily accessible and comprised of relatively conserved 
structures. A conserved target coupled with the rapid antimicrobial activity of membrane 
targeting antibiotics4 make resistance against membrane targeting antibiotics more difficult to 
select for.5 This makes targeting bacterial membranes an effective approach to combat slow-
growing or difficult to treat dormant bacteria.6 
 
1.2 The Bacterial Membrane 
 Bacterial membranes act as a semi-permeable barrier which controls the transport of 
molecules and provides protection to the cellular contents.7 All bacteria have an innermost 
cytoplasmic membrane, composed primarily of phospholipids. Gram-positive bacteria have a 
thick outer layer of peptidoglycan, while Gram-negative bacteria have a thin peptidoglycan layer 






The phospholipid composition of the cytoplasmic membrane of mammalian cells is 
distinct from bacteria, allowing for differentiation. The major mammalian phospholipids are 
zwitterionic sphingomyelin (SM) and phosphatidylcholine (PC), which afford neutral membranes 
(Figure 1-3A). In bacteria, especially Gram-positive species, the major phospholipids are anionic 
cardiolipin (CL) and phosphatidylglycerol (PG), generating anionic membranes. In some bacterial 
species, the cationic phospholipid lysyl-PG (Lys-PG) is also present, which can tune the membrane 
charge.8 Exploiting this charge difference allows for identification of bacteria in mammalian 
hosts. 
 




1.3 Staphylococcus aureus Phospholipids 
Gram-positive Staphylococcus aureus (S. aureus) cytoplasmic membranes are composed 
of three main types of phospholipids: CL, PG, and Lys-PG, which is the lysine ester of PG (Figure 
1-3B). The percentages of each relative to 
total phospholipids vary based on 
environmental conditions and stage of 
cell growth, but are typically around 38-
76% PG, 5-30% CL, and 14-38% Lys-PG.9,10 
Both PG and CL, also known as di-
PG, have negatively charged headgroups, 
generating net negatively charged 
bacterial membranes. However, the lysine 
residue of Lys-PG carries two cationic 
charges at physiological pH, which makes 
the headgroup cationic. By controlling the 
amount of Lys-PG displayed, bacteria can 
adjust their membranes to become more cationic, causing less potency from antibiotics that 
typically exploit the net negative bacterial membrane charge, such as cationic antimicrobial 
peptides (CAMPs).  
 
Figure 1-3: Structures of the major mammalian (A) 
and bacterial (B) phospholipids. Zwitterionic 
sphingomyelin (SM) and phosphatidylcholine (PC) 
primarily compose the mammalian cytosolic 
membrane, while anionic cardiolipin (CL) and 
phosphatidylglycerol (PG) are the main components of 
the bacterial cytosolic membrane. Cationic lysyl-PG 





1.4 Cationic Antimicrobial Peptides and Host Immunity 
CAMPs are short 12-50 residue peptides with a net cationic charge ranging from +2 to 
+7.11 They are ubiquitous throughout all species of life and are a key part of the innate immune 
system, possessing broad spectrum antimicrobial activity as well as more recently discovered 
immunomodulatory effects.12,13 While CAMPs have highly variable structures and sequences, 
they all possess two common features: 1) cationic charge due to the abundance of basic residues, 
such as arginine and lysine, and 2) amphiphilicity as they possess both hydrophilic cationic 
residues and hydrophobic residues (Table 1-1). While the cationic residues create an electrostatic 
attraction to the anionic bacterial membranes, the hydrophobic residues allow for partitioning 
of the peptides into the phospholipid membrane, inducing antimicrobial activity, typically 





Table 1-1: Structures and sequences of common mammalian cationic antimicrobial peptides. Adapted 






The majority of S. aureus phospholipids are anionic PG and CL, which attract CAMPs 
selectively to bacterial cells over the neutral mammalian cells.11 However, as the membrane 
becomes more cationic with increasing Lys-PG amounts, the electrostatic interaction between 
the membrane and CAMPs is disrupted, leading to CAMP resistance via decreased membrane 
binding and activity (Figure 1-5). 
 
1.5 Studies on Lys-PG Synthesis and CAMP Resistance 
 Although Lys-PG was first reported in the early 1960s22–24, the enzyme responsible for its 
synthesis, multiple peptide resistance factor (MprF), was not discovered until 2001.25,26 MprF is 
a transmembrane protein with two distinct functionalities: a soluble C-terminal Lys-PG synthase 
Figure 1-4: Membrane disrupting mechanisms of action of CAMPs. The barrel-stave (A), toroidal pore 
(B), and carpet (C) models of CAMP-induced bacterial killing. Adapted from Brogden, K. A. Nat Rev 
Micro 2005, 3 (3), 238. 
 
A B C 
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domain and a transmembrane N-terminal flippase domain, which flips the newly synthesized Lys-
PG from the inner leaflet to the outer leaflet.27,28 
Lys-PG is correlated with an increased resistance to various antibiotics, especially 
CAMPs.25,29,30 Up to a 30-fold decrease in minimum inhibitory concentration (MIC) of various 
CAMPs was observed in an mprF knockout S. aureus strain expressing no Lys-PG, in comparison 
to wild type S. aureus.25 Subsequent studies 
have corroborated those results, displaying 
increased susceptibility of the S. aureus 
mprF knockout to antibiotics such as 
vancomycin31, daptomycin27, and 
methicillin32, as well as CAMPs such as 
gallidermin.27 Significantly lower 
antimicrobial MIC values in vitro and 
attenuated virulence in mice carrying a mprF 
knockout further demonstrate the 
importance of Lys-PG to S. aureus resistance 
and pathogenicity.25 
Homologs of MprF have also been 
identified in a variety of other human 
pathogens, including Pseudomonas aeruginosa, Bacillus subtilis, Enterococcus faecalis, 
Mycobacterium tuberculosis, and Mycobacterium leprae.25 In total, 347 homologous sequences 
have been identified in 31 Gram-positive genera, 59 Gram-negative genera, and three species of 
Figure 1-5: Depiction of Lys-PG on a bacterial 
membrane (A) and the different membrane 
compositions between cationic antimicrobial 






archaea.29 Lys-PG has also been identified in some of those bacteria species25, as well as other 
aminoacyl-PG derivatives, such as Ala-PG and Arg-PG, suggesting that homologs from different 
species have different selectivities for which amino acid is loaded onto PG.29,33 
 
1.6 Other Membrane Charge Altering Modifications Leading to CAMP Resistance 
In addition to MprF-mediated lysyl modification of PG, staphylococci have also been 
found to modify teichoic acids with D-alanine through the dlt operon to reduce the negative 
charge of the cell wall, similarly modulating CAMP binding.34 Teichoic acids are the carbohydrate-
based polymers that comprise the S. aureus peptidoglycan layer outside of the cytoplasmic 
membrane. Moreover, amino-sugar glycosylation and phosphoethanolamine incorporation into 
the lipid A core of lipopolysaccharide in Gram-negative bacteria have also been shown to increase 
the overall charge of the outer membrane.5 
In addition to cell surface charge modification, staphylococci have evolved other CAMP 
resistance mechanisms, including non-specific proteases, efflux pumps, and biofilm formation 
(Figure 1-6). Generally, CAMP resistance mechanisms are upregulated upon CAMP detection by 
sensing systems, such as the antimicrobial peptide sensor ApsSRX (S. aureus homolog is the 
glycopeptide resistance-associated sensor GraSRX) and vancomycin-resistance associated genes 
VraFG.35 In the ApsSRX system, CAMP presence is detected via binding to a highly anionic 9 
residue extracellular loop on ApsS, the transmembrane sensor kinase. ApsS phosphorylates ApsR, 
the response regulator, which causes a cascade resulting in upregulation of MprF and the dlt 
operon. ApsX is a cytosolic protein of unknown function known to interact with ApsS and required 
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for transduction of the CAMP signal from ApsS to ApsR. VraFG encodes an ABC transporter, which 
must act in conjunction with the ApsSRX system to detoxify CAMPs from bacteria. Specifically, 






1.7 Peptide-based Antibiotics and Antibiotic Adjuvants 
 CAMPs initially gained attention as potentially novel antibiotics because of their 
membrane-targeting antimicrobial activity, but recent studies have shown their antimicrobial 
Figure 1-6: Various staphylococci CAMP sensing and resistance mechanisms. Adapted from Joo, H.-S.; 
Otto, M. Biochimica et Biophysica Acta (BBA) - Biomembranes 2015, 1848 (11, Part B), 3055–3061. 
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activity is significantly reduced in physiologically relevant salt concentrations, as well as in 
serum.11,15 However, increasing evidence has shown that membrane disruption is only one of the 
mechanisms of antimicrobial activity that CAMPs possess, in addition to immune modulation16, 
chemotactic activities, and inflammatory response management.11,13 Having multiple 
mechanisms of action makes CAMPs more attractive for use as novel antibiotics due to a lower 
risk of developing resistance.12 
CAMPs, especially host defense peptides, are not only being explored as novel 
antimicrobial drugs, but also as tunable innate antimicrobials.17 The latter could be achieved by 
treatment with an antibiotic adjuvant, which would not kill the bacteria on its own, but increase 
the potency of the host CAMPs. Thus, bacteria could be rendered re-susceptible to host CAMPs 
through membrane manipulation to increase their net negative charge. This strategy is ideal as 
it would boost the host’s own immune system without the need for administering an antibiotic 
and would theoretically avoid triggering resistance to the antibiotic adjuvant as it would not 
directly kill bacteria. 
A few such co-treatments have been reported recently, involving anti-MprF antibodies to 
prevent Lys-PG expression in combination with antibiotics such as daptomycin and nisin in S. 
aureus18, combinatorial β-lactam and daptomycin therapy to induce a cell surface charge 
reduction in clinical methicillin-resistant S. aureus (MRSA) strains19,20, or non-lethal outer 
membrane-active small molecules with antibiotics such as vancomycin, rifampicin, and 




1.8 Reversible Covalent Chemistries for Peptide Cyclization 
Cyclic peptides represent complex yet synthetically accessible moieties which could be 
utilized to target bacterial membranes as novel antibiotics or non-lethal membrane modifiers. 
Accessing cyclic peptide scaffolds is advantageous as it provides preorganization and higher 
target binding affinity. Although there are many strategies for peptide cyclization, most are not 
reversible, excluding disulfide chemistry.37 Reversibility is key as it could be used to tune the 
peptide activity to create responsive “smart” peptides, which could exert their own activity upon 
linearization or report on the presence of reactive metabolites. Discovering novel reversible 
covalent chemistries could be beneficial to developing peptide cyclization techniques. 
Of the wide array of bioorthogonal reactions available38,39, only a handful utilize reversible 
covalent chemistry, such as ortho-boronic acid functionalized iminoboronate formation.8,40–43 
Our lab previously demonstrated the rapid and reversible peptide cyclization between the ε-
amine of a lysine residue and a novel amino acid containing a 2-acetylphenylboronic acid (APBA) 
moiety.37 The ortho-boronic acid stabilizes the imine via formation of a dative bond upon 
condensation to form iminoboronates, allowing increased conjugate stability while maintaining 
rapid reversibility (Figure 1-7A). The iminoboronate-based peptide cyclization was found to be 
responsive to pH, oxidation, and small molecules, creating “smart” peptides that are stable to 
endogenous nucleophiles yet can be readily linearized upon orthogonal induction. 
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Taking advantage of the added reactivity of the aldehyde in 2-formylphenylboronic acid 
(FPBA) has enabled formation of iminoboronate-stabilized thiazolidines between free or N-
terminal cysteine residues and FPBA, 
called thiazolidino boronates (TzB) 
(Figure 1-7B).44 This strategy is 
advantageous because it utilizes an 
endogenous residue as one 
bioorthogonal reaction member while 
maintaining selectivity for the 1,2 
aminothiol moiety over simple amines 
or thiols. Exploring the scope of FPBA-
based reversible covalent chemistries could lead to more novel conjugation chemistries. Adding 
reversible reactions to the bioorthogonal “toolbox” enables expansion of possible applications.  
 
1.9 Experimental Goals 
In efforts to find novel antibiotic adjuvants, I have been exploring various ways to 
modulate S. aureus surface charge by targeting membrane amines, such as Lys-PG, with peptides 
and small molecules to increase bacterial susceptibility to CAMPs. This offers an advantage over 
genetic manipulations and knockout strains as we can study the electrostatic influence of CAMP 
effectiveness alone by directly manipulating the membrane surface charge. The reactivity of the 
Lys-PG headgroup’s free amine can be utilized for peptide binding and small molecule 
Figure 1-7: Reversible covalent chemistries between APBA 





modification to neutralize the cationic charge and increase the membrane’s net negative charge, 
with the goal of enabling more efficient CAMP activity. 
A second project involves exploring novel FPBA-based reversible covalent chemistries for 
peptide cyclization applications. Expanding the repertoire of cyclization reactions is desirable as 
cyclic peptides possess enhanced biostability and binding affinity compared to linear peptides. 
These novel cyclic peptides could either be explored as antimicrobial drugs or non-lethal bacterial 
membrane-targeting antibiotic adjuvants. 
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CHAPTER 2: TARGETING AMINES ON THE STAPHYLOCOCCUS AUREUS 




2.1 Lys-PG Binding Using Peptides 
 Previously in our lab, two peptides were discovered that bind potently to S. aureus or Lys-
PG specifically: KAM-CT, a cyclic peptide containing three APBA moieties, which bind S. aureus 
surface amines through iminoboronate formation; and MAK3, a linear peptide containing two 
APBA moieties. KAM-CT is a potent S. aureus binder (Kd = 100-200 nM) while MAK3 specifically 
binds to Lys-PG potently (S. aureus Kd = 50-100 nM). MAK3 was identified as a specific Lys-PG 
binder through phage display by directly screening against Lys-PG. The potency of these peptides 
as antibiotic adjuvants was examined by treating S. aureus with each peptide followed by CAMP 
treatment of Gramicidin A3R, a cationic Gramicidin A mutant developed in our lab; Protegrin-1, 
a highly cationic porcine defensin; or Vancomycin, a slightly cationic glycopeptide (Figure 2-1). 
 
 
Figure 2-1: Structures of Lys-PG binding peptides and cationic antimicrobial peptides used for S. aureus 
treatment. Insert shows general iminoboronate formation between an amine and the APBA moiety on 
the Lys-PG binding peptides. APBA-functionalized side chains are indicated in blue. 
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2.1.1 Protegrin-1 Synthesis 
While KAM-CT, MAK3, and Gramicidin A3R were provided by other lab members and 
Vancomycin was purchased, Protegrin-1 had to be synthesized. Based on previously reported 
syntheses1–5, Protegrin-1 was synthesized using Fmoc-based SPPS. After N-terminal Fmoc 
deprotection and cleavage from resin, the crude peptide was reduced with dithiothreitol then 
purified using RP-HPLC. Air oxidation in PBS (pH 7.4) gave the oxidized peptide, which was 
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Circular dichroism (CD) of pure oxidized Protegrin-1 was performed to verify the correct folding 
into a β-hairpin structure. The overall shape matches that expected of the correctly folded β-
hairpin structure (Figure 2-3).1 
 
2.1.2 Lys-PG Binding Peptide and CAMP Co-Treatments 
Upon Lys-PG binding through iminoboronate formation, the positive charge on a Lys-PG 
headgroup amine will be removed, yielding an overall more anionic surface charge. This decrease 
in surface charge should cause increased activity of the CAMPs due to higher electrostatic 
attraction to the membrane. 
Both KAM-CT (up to 10 μM) and MAK3 (up to 5 μM) alone did not kill S. aureus, meaning 














Protegrin-1 Circular Dichroism 
Figure 2-3: CD of oxidized Protegrin-1 to verify the correct β-hairpin structure. 
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from the adjuvant peptide. Concentrations above S. aureus membrane saturation values were 
used for both peptides: above 1 μM and 500 nM for KAM-CT and MAK3, respectively. 
Increased killing was seen after KAM-CT co-treatment with Gramicidin A3R and Protegrin-
1 compared to each CAMP alone. However, there was no significant difference in killing with or 




Co-treatment with MAK3 did not cause any significant difference in S. aureus killing with 
any of the CAMPs. MAK3 has two cationic residues; therefore, upon binding two Lys-PG amines 
and diminishing the surface charge by two, it brings two additional charges with its residues, 
making the change in net surface charge zero. If the net surface charge did not change, the 
effectiveness of the CAMPs should not change either, which agrees with the experimental results. 
Figure 2-4: MIC assay results with KAM-CT and CAMP co-treatment plotted as concentration of CAMP 
(μM) versus OD600. CAMP alone is purple, 5 μM KAM-CT is light blue, and 10 μM KAM-CT is dark blue. 
CAMP concentrations where a significant difference was seen after KAM-CT treatment are indicated 
by the green boxes and values. Gramicidin A3R data obtained by Breanna Zerfas. 
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2.2 Lys-PG Modification Using Small Molecules 
 Instead of binding Lys-PG with peptides, directly modifying Lys-PG was next explored 
using small molecules. Two modifications were employed: acetylation of Lys-PG headgroup 
amines with sulfo-NHS-acetate to reduce the net positive charge of the membrane; and cleavage 
of the lysine residue to regenerate the anionic PG headgroup (Scheme 2-1). Lysine cleavage 
would be more beneficial as it would regenerate an endogenous lipid as well as decrease the 
cationic charge of the membrane. 
 
 
2.2.1 Lys-PG Acetylation 
To quantify the extent of Lys-PG acetylation with various concentrations of sulfo-NHS-
acetate, small unilamellar vesicle (SUV) liposomes composed of 3:1 PG:Lys-PG were used as 
models to mimic the phospholipid composition of S. aureus. After acetylation, the lipids were 
extracted and examined via negative ESI-MS, where the ion intensities were measured and used 
to calculate the percentage of Lys-PG that was acetylated. With 1 mM sulfo-NHS-acetate 
Scheme 2-1: Lys-PG modification via amine acetylation (top) or small molecule nucleophilic lysine 
cleavage to regenerate PG (bottom). 
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treatment, about 30% of the Lys-PG was acetylated and 10mM treatment gave 65-80% Lys-PG 
acetylation. For S. aureus treatment, 10 mM sulfo-NHS-acetate was chosen to achieve the most 
acetylation. 
 S. aureus acetylation without CAMP treatment was shown to cause 35% killing, which was 
taken into consideration when calculating the increase in killing seen with CAMP treatment 
(Figure 2-5A). Wild type Gramicidin 
A (gA WT) was used as a positive 
control to ensure complete bacterial 
killing. Acetylation followed by 
Gramicidin A3R or Protegrin-1 
treatment gave an average of 2.5x 
and 10x increased killing compared 
to each CAMP treatment alone, 
respectively (Figure 2-5B). These 
results agree with the Lys-PG 
binding peptide-induced increase in 
CAMP activity seen previously. 
Therefore, altering S. aureus 
membrane charge to be less cationic 
can modulate CAMP activity by 
exploiting an increased electrostatic 
interaction. 
Figure 2-5: S. aureus acetylation followed by Gramicidin 
A3R and Protegrin-1 treatment. A) Treatment with 10 mM 
sulfo-NHS-acetate followed by triplicate Gramicidin A3R 
treatment. * Indicates killing caused by acetylation alone. ** 
Indicates a synergistic increase in killing seen with co-
treatment compared to additive Gramicidin A3R and 
acetylation killing. B) Percent S. aureus survival with (blue) 
and without (purple) acetylation treatment followed by 





2.2.2 Lys-PG Cleavage with Pig Liver Esterase 
 First, specific Lys-PG cleavage was explored using pig liver esterase to selectively cleave 
the lysine ester bond of the Lys-PG headgroup. 3:1 PG:Lys-PG liposomes were treated with a 
range of esterase concentrations and the lipids were extracted with chloroform. No lipid masses 
were seen from the lipid extracts upon ESI-MS analysis, making esterase treatment inconclusive. 
 
2.2.3 Lys-PG Cleavage with Hydrazine- and Hydroxylamine-based Nucleophiles 
 Lys-PG cleavage was next explored using non-specific small molecule nucleophiles. A 
panel of hydrazine- and hydrazide-based nucleophiles were evaluated for Lys-PG cleavage 
efficiency using liposome models and ESI-MS analysis. Initial screening involved harsh conditions 
of 1 M nucleophile with overnight liposome treatment to identify sufficiently active nucleophiles, 
ideally ones that would cause complete Lys-PG cleavage under those conditions. Acetyl 
hydrazide, semicarbazide, and p-carboxy-phenylhydrazine showed increasing Lys-PG cleavage, 
corresponding to increase nucleophilicity, but did not cause enough cleavage to be meaningful 
(less than 60% Lys-PG cleavage). The most nucleophilic small molecules, hydrazine and 
hydroxylamine, both showed complete Lys-PG hydrolysis (Figure 2-6A). To explore their 
reactivity at more biologically relevant conditions, 10 mM, 100 mM, and 1 M of each were 
incubated with liposomes for 1 hour. Significant Lys-PG cleavage was only seen at the 1 M 
concentration (Figure 2-6B). That was not ideal as 1 M is too concentrated to be biologically 







2.2.4 Hydrazine or Hydroxylamine-Induced Cleavage of Lys-OMe 
The speed of hydrazine- and hydroxylamine-induced ester cleavage was examined using 
lysine methyl ester as a model of the Lys-PG headgroup. The kinetics of 10 mM lysine methyl 
ester cleavage with 1 M hydrazine or hydroxylamine was studied using 1H NMR in PBS (pH 8.0). 
The disappearance of the lysine ester methyl peak and appearance of the methanol methyl peak 
was monitored over time to determine the amount of methanol present. The percent methanol 
was plotted against time to generate a curve from which t1 values of 3.88 and 3.16 hours were 
calculated for hydrazine and hydroxylamine, respectively (Figure 2-7). 
 
Figure 2-6: Lys-PG Cleavage with Small Molecule Nucleophiles. A) Overnight incubation of 1 M of 
each small molecule with 3:1 PG:Lys-PG liposomes. B) 1-hour incubation with 10 mM to 1 M 
hydrazine or hydroxylamine with 3:1 PG:Lys-PG liposomes. Percent Lys-PG cleavage measured by the 
relative ion intensity of DOPG produced from Lysyl-DOPG via negative ESI-MS. 1-hour liposome 







Because the cleavage kinetics is slow, increasing the concentration of hydroxylamine at 
the membrane surface would increase cleavage potency. Hydroxylamine could be conjugated to 
a membrane-binding peptide, which would decrease the concentration of hydroxylamine-
Figure 2-7: Lysine Methyl Ester Cleavage with 1 M Hydrazine (A) or Hydroxylamine (C) via 1H NMR. 
The percent cleavage was calculated by integrating and comparing the ester methyl (red arrow) and 
methanol methyl (green arrow) peaks. The percent methanol was plotted against time to generate a 
curve, which was fit with an exponential equation to generate the t1 values (B, D). 
C 
B 
t1 = 3.88 h 
A 




conjugated peptide required for sufficient activity. This was examined by directly conjugating 
hydroxylamine to a small CAMP. 
 
2.3 Activity of a Hydroxylamine-Functionalized CAMP: AOA-Hlys 
 A 9-residue fragment of human lysozyme, called Hlys, was chosen as a model CAMP due 
to its staphylocidal activity6 and the ease of its synthesis and modification. A glycine linker was 
added to the N-terminus and the hydroxylamine was installed via amide bond formation between 
the N-terminal amine and the carboxylic acid of aminooxyacetic acid (AOA) (Figure 2-8A). 
The Lys-PG cleavage efficacy of the peptide conjugate, called AOA-Hlys, compared to 
hydroxylamine and Hlys alone were compared using 3:1 PG:Lys-PG liposome models. After lipid 
extraction and ESI-MS analysis, the AOA-Hlys peptide conjugate showed about 2-fold increase in 
Lys-PG cleavage compared to hydroxylamine alone. Surprisingly, Hlys also displayed Lys-PG 
cleavage activity greater than hydroxylamine, but less than AOA-Hlys (Figure 2-8B). Hlys was not 
anticipated to have cleavage ability as there are no nucleophilic residues; it was just anticipated 
to bind and insert into the membrane. 
The cell killing capability of the AOA-Hlys conjugate was compared to Hlys in the hopes of 
showing increased killing with the conjugate due to nucleophilic cleavage of Lys-PG and 
regeneration of PG. However, Hlys showed greater S. aureus killing activity than AOA-Hlys (Figure 
2-6C). The only difference between Hlys and AOA-Hlys is the AOA moiety on the N-terminus, 




To study what is happening to the membrane more closely, evaluation of peptide 
membrane binding and quantification of Lys-PG following various treatments is desirable. 
Figure 2-8: A) Cartoon (inset) and structure of the hydroxylamine-Hlys peptide conjugate, AOA-Hlys. 
B) Liposomes treated with 1 mM hydroxylamine, Hlys, and AOA-Hlys to examine Lys-PG cleavage at 1 
h, 3 h and overnight incubations. C) S. aureus killing comparing Hlys (purple) to the AOA-Hlys conjugate 






2.4 Hlys and AOA-Hlys Liposome Binding 
 Binding of Hlys and AOA-Hlys peptides to 3:1 PG:Lys-PG liposomes was examined via 
tryptophan (Trp) fluorescence, which was previously used to study peptide-membrane 
interactions.7–10 After excitation at 280 nm, Trp emits between 340-350 nm with a blue shift and 
increase in fluorescence intensity occurring as the side chain moves into a more hydrophobic 
environment.7 The binding of Hlys (1 μM) with increasing the concentrations of liposomes (25-
100 μM) showed the characteristic blue shift and fluorescence intensity increase (Figure 2-9). 




2.5 Lys-PG Quantification 
 Phospholipids can be extracted from bacteria using a modified Bligh and Dyer method11 
then separated and visualized using two main methods. First, 1D or 2D thin layer chromatography 
Figure 2-9: Binding of Hlys and AOA-Hlys peptides to 3:1 PG:Lys-PG liposomes in phosphate buffer, pH 
7.4. Tryptophan fluorescence was recorded with increasing concentrations of liposomes (25-100 μM) 
with 1 μM Hlys or AOA-Hlys. The wavelengths with the maximum fluorescence with each liposome 
concentration are indicated as the data point on each spectrum. 
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(TLC) of the phospholipid extracts can be stained with a phosphate-specific molybdenum stain or 
an amine-specific ninhydrin stain.12,13 Second, normal-phase high performance liquid 
chromatography (NP-HPLC) can be used to detect phospholipids via absorbance at a non-specific 
wavelength, such as 200-210 nm14,15, or the more sensitive evaporative light scattering detection 
(ELSD) method.16,17 For lipid quantification, bacteria can be grown in the presence of a radioactive 
metabolite, such as 32P, and extracted to obtain the phospholipids. After TLC separation, the 
radioactivity of each spot, corresponding to a specific type of phospholipid, can be measured. 
Alternatively, the area under the peaks from the HPLC trace can be quantified and the 
concentrations of each lipid could be estimated using the known concentration of an internal 
standard. 
 
2.5.1 Phospholipid 1D TLC 
 Following lipid extraction, the isolated phospholipids from the chloroform layer were 
spotted onto TLC plates and developed in 65% chloroform : 30% methanol : 5% acetic acid until 
the solvent front reached the top of the plate (less than 10 minutes). Lipids were visualized using 
the amine-specific stain ninhydrin or the phosphate-specific stain ceric ammonium molybdate 
(CAM) (Figure 2-10). Although the phospholipids were successfully isolated, separated, and 
identified using lipid standards, they were not easily quantified. Previous quantification using TLC 
studied the Lys-PG differences between wild type S. aureus and gene knockouts producing no 





2.5.2 Phospholipid Normal-Phase Analytical HPLC 
 To expand the possible detection methods, normal-phase HPLC was attempted on 
phospholipid extracts with various detection methods. Although previous reports indicated 
phospholipid separation and visualization using absorbance at 205 nm, neither lipid extracts nor 
phospholipid standard solutions could be visualized at that wavelength. 
 Taking advantage of the amine reactivity of the Lys-PG headgroup and the sensitivity of 
the carboxyfluorescein (FAM) fluorophore, Lys-PG can be specifically fluorophore-labeled, and 
the conjugate can be detected at 495nm. Optimal fluorophore labeling conditions were found to 
be lipids reacted with excess NHS-FAM (1 mM) and triethylamine (1 μL) in chloroform (50 μL total 
reaction volume) for 2 hours at room temperature. Ethylenediamine (EDA, 10 mM) was added to 
quench the remaining NHS-FAM because the retention time of NHS-FAM was very close to that 
of FAM-Lys-PG. The EDA-FAM adduct has a much more delayed retention time, allowing for easy 
peak integration. That adduct peak can be used as an internal standard for compare with the 
FAM-Lys-PG peak. A range of Lys-PG concentrations were used (50 μM – 500 μM), all of which 
were successfully labeled. FAM-Lys-PG (10 μL) from the 50 μM reaction could be detected as a 
Ninhydrin CAM 
Figure 2-10: Example 1D TLC of 
phospholipids extracted from S. aureus 
stained with amine-specific ninhydrin (left) 
or phosphate-specific CAM (right). Lys-PG 
and PG standards are included.  
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clear peak on the analytical HPLC, indicating a detection limit of approximately 2-3 pmol FAM-
Lys-PG at 495 nm. 
 The ability to detect and quantify phospholipids extracted from S. aureus was assessed 
using this fluorophore-labeled HPLC method. After lipid extraction, NHS-FAM labeling, and 
ethylenediamine NHS-FAM quenching, the crude labeling reaction was analyzed directly via NP-
HPLC (Figure 2-11A). Each peak was collected and analyzed via positive and negative MS loop 
injections. Both major peaks around 34-35 min corresponded to FAM-Lys-PG with the major ion 
being derived from Lys-PG with two 16:0 acyl chains ([M+H]+ = 1209.6 and [M-H]- = 1207.6). 
Differences of 14 mass units correlate with the addition or loss of a methylene (CH2) from the 
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Counts vs. Mass-to-Charge (m/z)
1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280
C 
Figure 2-11: Example analytical NP-HPLC of fluorescein-labeled Lys-PG after extraction from untreated 
S. aureus (A). Positive (B) and negative (C) MS of the main peak at 34 min show the masses of FAM-
Lys-PG species, with differences of 14 corresponding to a methylene addition or loss in the acyl chain. 
33 
 
 This HPLC protocol was used to study the unmodified Lys-PG content found in S. aureus 
after acetylation with 10 mM sulfo-NHS-acetate, as previously studied using liposome 
modification and S. aureus cell killing. After 10 mM sulfo-NHS-acetate treatment, lipid extraction, 
NHS-FAM labeling, and ethylenediamine NHS-FAM quenching, the amount of FAM-Lys-PG was 
quantified (Figure 2-12A,B). The percent of FAM-Lys-PG was calculated by dividing the area under 
the FAM-Lys-PG peaks by the total area under the FAM-Lys-PG and EDA-FAM peaks, representing 
the total amount of NHS-FAM originally present (Figure 2-12C). After acetylation, there was 58% 
the amount of FAM-Lys-PG present from untreated S. aureus, indicating approximately 40% of 
the bacterial Lys-PG was acetylated and unable to react with NHS-FAM. This complemented the 
liposome MS analysis, which indicated 65-80% acetylation with 10 mM sulfo-NHS-acetate. 
Therefore, both the MS analysis and this HPLC method were reliable ways to probe the reactivity 





























































 The Lys-PG cleavage ability of Hlys with liposomes was also explored using this HPLC 
protocol. 3:1 PG:Lys-PG liposomes were treated with Hlys (10 and 100 μM) overnight at room 
temperature. After lipid extraction, NHS-FAM labeling, and ethylenediamine NHS-FAM 
quenching, there was no significant difference in the amount of FAM-Lys-PG: untreated S. aureus 
gave 10.1 ± 0.5% FAM-Lys-PG and S. aureus treated with 100 μM Hlys gave 8.9 ± 2.4% FAM-Lys-
PG. This is not surprising as Hlys was not expected to cause Lys-PG cleavage, but this contrasts 
the data from ESI-MS analysis. Knowing this, the data from ESI-MS analysis can be interpreted 
with caution and this HPLC protocol can be used to verify (or refute) the ESI-MS data. 
 
2.6 Conclusions 
 Modulating the bacterial membrane charge allows for increased susceptibility to certain 















Untreated and Acetylated S. aureus
FAM-Lys-PG Quantification
Figure 2-12: Example analytical HPLC of fluorescein-labeled Lys-PG after extraction from untreated S. 
aureus (A) or S. aureus treated with 10 mM sulfo-NHS-acetate (B). The peaks corresponding to FAM-
labeled Lys-PG (2 peaks, 33-34 min), hydrolyzed NHS-FAM (COOH-FAM, 44.5 min), and the 
ethylenediamine-FAM adduct (EDA-FAM, 46 min) are labeled. Percent FAM-Lys-PG was determined 




dependent inhibition of S. aureus growth after Gramicidin A3R and Protegrin-1 treatments. This 
is presumably due to increased CAMP activity resulting from the lowering of surface charge by 
elimination of cationic free amines through iminoboronate formation. 
Sulfo-NHS-acetate was used to acetylate Lys-PG, as demonstrated through model 
liposome labeling analyzed via ESI-MS and labeling of S. aureus analyzed via fluorophore labeling 
the lipid extracts followed by NP-HPLC. Acetylating surface amines to remove their cationic 
charge caused S. aureus to become 2.5 and 10 times more susceptible to Gramicidin A3R and 
Protegrin-1, respectively. 
 Nucleophilic Lys-PG cleavage was achieved by hydroxylamine and a hydroxylamine-
functionalized CAMP, AOA-Hlys. The AOA-Hlys conjugate increased Lys-PG cleavage by about 2-
fold in liposomes compared to hydroxylamine alone, as determined via ESI-MS. However, Hlys 
killed S. aureus more effectively than the AOA-Hlys conjugate, contrary to the hypothesis that 
the hydroxylamine would promote Lys-PG cleavage and regenerate a more anionic membrane 
surface. Analysis of Hlys and AOA-Hlys liposome binding via Trp fluorescence revealed 
comparable binding. ESI-MS analysis of Lys-PG cleavage from liposomes treated with either Hlys 
or AOA-Hlys revealed that Hlys also caused Lys-PG cleavage, which was unexpected as it does not 
contain any nucleophilic residues. However, fluorophore labeling and NP-HPLC analysis revealed 
no significant difference in FAM-Lys-PG levels between untreated S. aureus and S. aureus treated 
with 100 μM Hlys. Therefore, the results from the ESI-MS analysis should be interpreted with 
caution as error caused by ionization or fragmentation cannot be ruled out. The HPLC analysis 
protocol is more reliable as it uses a well-established NHS-based fluorophore labeling chemistry 
and analytical method. 
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2.7 Experimental Procedures 
2.7.1 General Methods 
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (sodium salt) (POPG) and 1,2-
dioleoyl-sn-glycero-3-[phospho-rac-(3-lysyl(1-glycerol))] (chloride salt) (Lysyl-DOPG) were 
purchased from Avanti Polar Lipids (Alabaster, AL). Vancomycin hydrochloride was purchased 
from Chem-Impex International (Wood Dale, IL). All other chemicals were purchased from Fisher 
Scientific (Pittsburgh, PA) or Sigma Aldrich (St. Louis, MO), unless otherwise indicated. Gram-
positive Staphylococcus aureus (ATCC 6538) were purchased as lyophilized cell pellets from 
Microbiologics (Cloud, MN). Peptide synthesis was carried out on a Tribute peptide synthesizer 
(Protein Technologies, Tucson, AZ). Peptide purification was performed on a Waters PrepLC 
system using a Phenomenex Jupiter C18 column (Torrance, CA). MIC data was obtained using a 
SpectraMax M5 microtiter plate reader (Molecular Devices, Sunnyvale, CA). 1x (10 mM) PBS 
buffer was used for all experiments at the indicated pH values. The peptide concentrations of all 
peptides used in MIC assays were determined by measuring their absorbance at a specified 
wavelength (below) on a NanoDrop 2000c UV-vis spectrometer either by cuvette or 1μL 
NanoDrop measurements. The extinction coefficients were either calculated by the number of 
Trp residues (ε = 5,560 M-1cm-1), APBA moieties (ε = 9,795.5 M-1cm-1), or FAM fluorophores (ε = 
80,000 M-1cm-1) present or found in the literature, as indicated in the following table. 
Peptide Wavelength (nm) Extinction Coefficient (M-1cm-1) 
KAM-CT 280 29,386.5 (3 APBA moieties) 
MAK3 495 80,000 (1 FAM fluorophore) 
Gramicidin A3R 280 22,240 (4 Trp residues) 
Protegrin-1 278 1520 (1 Tyr, 1 Phe, 2 disulfide bonds)1 
Vancomycin 280 5942.8 
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2.7.2 Peptide Synthesis and Characterization 
All peptides were synthesized using standard Fmoc-based SPPS on Rink Amide MBHA resin. They 
were carried out on a 0.05 mmol scale using 5 equivalents of each amino acid and 4.75 
equivalents of HBTU for each coupling reaction. All peptides had a purity of 90% or higher. KAM-
CT and MAK3 were synthesized and provided by Kelly McCarthy and Michael Kelly, respectively. 
Gramicidin A3R synthesis was previously reported20 and provided by Breanna Zerfas. 
Protegrin-1 Synthesis 
After Fmoc SPPS and N-terminal Fmoc deprotection, the crude peptide was cleaved off resin and 
globally deprotected with 90% trifluoroacetic acid : 5% water : 5% thioanisole treatment for 2.5 
hours. Cold ether precipitation yielded crude peptide, which was dissolved in water and 
lyophilized. The crude lyophilized peptide (35 mg, 0.016 mmol) was dissolved in 5 mg/mL urea (7 
mL) and reduced with dithiothreitol (14 eq, 0.227 mmol) via stirring overnight at room 
temperature.1 The reduced peptide was purified using RP-HPLC, monitoring at 214 nm (amide 
bonds), and lyophilized. The lyophilized reduced peptide was dissolved in PBS (pH 7.4) and stirred 
open to the atmosphere for approximately 36 hours at room temperature. Oxidation was 
complete at 8 hours, as indicated by LC-MS analysis. Crude oxidized peptide was purified using 
RP-HPLC, monitoring at 214 nm, and lyophilized. Peptide purity was assessed by LCMS. For 




Circular dichroism (CD) was performed to verify the correct oxidation of the disulfide bonds. 
Oxidized Protegrin-1 (68 μM) in PBS (pH 7.4) was scanned from 190 to 250 nm at 25°C. A PBS 
buffer blank was subtracted to generate the final CD spectrum. 
Hlys & AOA-Hlys Synthesis 
After SPPS and N-terminal Fmoc deprotection, Hlys was globally deprotected and cleaved off 
resin via Reagent K (82.5% trifluoroacetic acid : 5% water : 5% thioanisole : 5% phenol : 2.5% 1,2-
ethanedithiol) treatment for 2 hours. The peptide was precipitated with cold ether then purified 
via RP-HPLC and lyophilized. 
The hydroxylamine moiety was added to the free N-terminus of Hlys on resin via addition of 
aminooxyacetic acid. Boc-aminooxyacetic acid (5 eq) was activated with HBTU (4.7 eq) in 0.4 M 
NMM in DMF for 5 min then added to the on-resin peptide, stirring for 1.5 hours. AOA-Hlys was 
globally deprotected and cleaved off resin via Reagent K (82.5% trifluoroacetic acid : 5% water : 
5% thioanisole : 5% phenol : 2.5% 1,2-ethanedithiol) treatment for 3 hours. The peptide was 
precipitated with cold ether then purified via RP-HPLC and lyophilized. Due to the known 
reactivity of the hydroxylamine moiety with acetonitrile21, the HPLC samples were prepared and 
purified immediately. 
2.7.3 Minimal Inhibitory Concentration (MIC) Assay 
S. aureus growth in the presence of membrane binding peptides and CAMPs were assessed using 
the standard microbroth dilution method.22 A single colony was selected from an LB agar plate 
and grown in LB media overnight at 37°C with agitation. The next morning, the culture was 
diluted 100 times into fresh LB media and grown until an OD600 value between 0.5 and 0.6 was 
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reached. The culture was diluted to approximately 5 x 105 colony forming units per mL (cfu/mL) 
using a previously calculated factor. Diluted culture (200 μL) was added to each well of a sterile 
96-well plate. Either KAM-CT (stock in water) or MAK3 (stock in water/DMSO mixture) were 
added to final concentrations of either 5 or 10 μM. Finally, 2μL of 2-fold serially diluted 
Gramicidin A3R (stock in DMSO), Protegrin-1 (stock in DMSO), or Vancomycin (stock in water) 
were added in triplicates. The plate was incubated at 37°C in a microtiter plate reader overnight. 
The OD600 value was recorded every 10 minutes after 15 seconds of shaking. The time when 
untreated S. aureus began to reach stationary phase was chosen to compare OD600 values of each 
treated sample. 
2.7.4 Cell Killing Assay 
S. aureus survival after sulfo-NHS-acetate and CAMP co-treatment was assessed. A single colony 
was selected from an LB agar plate and grown in LB media overnight at 37°C with agitation. The 
next morning, the culture was diluted 100 times into fresh LB media and grown until an OD600 
value between 0.5 and 0.6 was reached. The bacteria were pelleted via centrifugation at 5,000 
rcf for 5 min, washed with PBS twice, and re-centrifuged. Approximately 1 x 107 cfu/mL of 
bacteria were treated with 10 mM sulfo-NHS-acetate in PBS (pH 8.5, 1 mL total reaction volume) 
for 1 hour at room temperature. The bacteria were pelleted via centrifugation, washed with PBS, 
and resuspended in PBS (pH 8.5, 1 mL). PBS (pH 8.5, 95 μL) was added to each well of a sterile 
96-well plate. The culture in PBS (5 μL, approximately 5 x 105 cfu/mL) and CAMP stock (in DMSO) 
or DMSO (1 μL) were added to the wells to give the desired CAMP concentrations. The plate was 
incubated at 37°C for 1 hour with shaking. The bacteria were directly diluted to approximately 
2.5 x 104 cfu/mL (7.5 μL reaction in 142.5 μL PBS, pH 8.5) and aliquoted (100 μL) onto LB agar 
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plates. After overnight growth at 37°C, the colonies on each plate were counted. Triplicate 
acetylation reactions and CAMP treatments were performed. To calculate the percent survival, 
the average number of colonies for each treatment condition was divided by the average number 
of colonies for comparable blank samples (either acetylated S. aureus or untreated S. aureus) and 
multiplied by 100. Percent killing is defined as 100 minus the percent survival. 
This protocol was also used to study S. aureus survival after Hlys or AOA-Hlys treatment at 100 
μM or 1 mM concentrations. 
2.7.5 Small Molecule and Peptide Liposome Treatment 
SUV Liposomes were prepared by aliquoting the desired amount of POPG and Lysyl-DOPG stocks 
(in chloroform) into a small glass vial and evaporating the chloroform. The lipid film was dissolved 
in PBS (pH 8.0) and immediately ultra-sonicated at 65% amplitude in short pulses until the 
solution was uniformly cloudy. Liposomes were used immediately after preparation. 
Acetylation 
3:1 PG:Lys-PG liposomes (50 μM total lipids per reaction) were prepared in PBS (pH 8.0, 200 μL 
total volume per reaction). Sulfo-NHS-acetate stock (in deionized water) was added to make 
either 1 mM or 10 mM final concentrations. Reactions were stirred for 1 hour at room 
temperature then the lipids were extracted with chloroform (200 μL, twice). Lipids were analyzed 





Pig Liver Esterase 
3:1 PG:Lys-PG liposomes (50 μM total lipids per reaction) were prepared in PBS (pH 8.0, 200 μL 
total volume per reaction). Esterase stock (in deionized water) was added to give 1 to 10 U of 
enzyme activity. Reactions were stirred for 45 min at room temperature then the lipids were 
extracted with chloroform (200 μL, twice). Lipids were analyzed via negative APPI-MS. 
Hydrazine-based Small Molecules 
3:1 PG:Lys-PG liposomes (50 μM total lipids per reaction) were prepared in PBS (pH 8.0, 200 μL 
total volume per reaction). Stocks of each of the following small molecules (in PBS) were tuned 
to pH 8.0 and added to liposomes to give the final concentration (1 mM – 1 M): acetic hydrazide 
(acetyl hydrazide), semicarbazide hydrochloride, 4-hydrazinobenzoic acid (p-carboxy-
phenylhydrazine), hydrazine monohydrate, and hydroxylamine hydrochloride. Reactions were 
stirred for 1-3 hours or overnight at room temperature then the lipids were extracted with 
chloroform (200 μL, twice). Lipids were analyzed via negative ESI-MS. 
Hlys and AOA-Hlys Peptides 
3:1 PG:Lys-PG liposomes (50 μM total lipids per reaction) were prepared in PBS (pH 8.0, 100 μL 
total volume per reaction). Hlys or AOA-Hlys stocks (in PBS) were tuned to pH 8.0 and added to 
each reaction to make a final concentration of 1 mM. Reactions were stirred for 1-3 hours or 
overnight at room temperature then the lipids were extracted with chloroform (200 μL, twice). 
Lipids were analyzed via negative ESI-MS. 
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2.7.6 Lipid ESI-Mass Spectrometry Analysis 
Lipid extracts from liposomes were analyzed via negative ESI-MS by comparing the ionization of 
POPG compared to DOPG and/or Lysyl-DOPG. Lipids were either used directly after chloroform 
extraction or dissolved in minimal chloroform (at least 20 μL). 10 μL of lipid sample was injected 
into the MS via loop injection and analyzed using an isocratic solvent of 99.9% methanol : 0.1% 
ammonium hydroxide over 2 minutes. Negative ion mode was used for all analyses as both PG 
and Lys-PG were able to be seen, although Lys-PG (cationic) did not ionize as well as PG (anionic). 
The discrepancy between the calculated molar ratio of PG to Lys-PG (3:1) and actual ion intensity 
seen (10:1) lead to a correction factor (0.3) being applied to PG ionization. The corrected PG ion 
intensity and raw Lys-PG ion intensity values were summed to get the total ion intensity. The 
percent of each lipid is defined as the following: (lipid ion intensity)/(total ion intensity) * 100. 
To determine the extent of Lys-PG acetylation, the percentage of mono-Ac-Lysyl-DOPG, di-Ac-
Lysyl-DOPG, and Lysyl-DOPG were summed to obtain the original amount of Lys-PG. The percent 
Lys-PG acetylation is defined as (% mono-Ac-Lysyl-DOPG + % di-Ac-Lysyl-DOPG)/(original amount 
of Lys-PG) * 100. 
To determine the extent of Lys-PG cleavage, the percent of DOPG produced from Lysyl-DOPG 
was calculated by summing the percent DOPG and percent Lysyl-DOPG to obtain the original 
amount of Lys-PG. The percent Lys-PG cleavage is defined as (% DOPG)/(original amount of Lys-
PG) * 100. 
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2.7.7 Hydrazine or Hydroxylamine-Induced Lys-OMe Cleavage NMR Kinetic Study 
A 600 μL NMR sample of either 1 M hydrazine or hydroxylamine in 20% D2O/PBS was prepared 
and tuned to pH 8.0. 6 μL of a 1 M Lys-OMe stock in PBS (pH 8.0) was added to the NMR sample 
to give a final concentration of 10 mM. The 1H NMR was recorded immediately and at certain 
intervals over 22 or 24 hours. The methyl peak of methanol and the methyl peak of Lys-OMe 
were integrated and compared to determine the percent cleavage (reported as percent 
methanol). The percent methanol was calculated as the following: (methanol methyl peak 
area)/(methanol methyl peak area + Lys-OMe methyl peak area) * 100. After plotting the time 
versus percent methanol, the points were fit to an exponential association curve, from which a 
t1 value could be extracted. 
2.7.8 Tryptophan Fluorescence  
A 3:1 PG:Lys-PG liposome stock (100 μM total lipids) was prepared as described above in PBS 
(pH 8.0). 0.55 mM Hlys and AOA-Hlys stocks (in PBS) were made and tuned to pH 8.0. For each 
fluorescence sample, 600 μL of liposomes (25, 50, or 100 μM final liposome concentrations) 
was aliquoted into a quartz microcuvette. Hlys or AOA-Hlys stock (1.1 μL) was added (1 μM final 
peptide concentration) and gently inverted to mix directly in the cuvette. The sample was 
excited at 280 nm and the fluorescence emission spectrum was recorded from 300 to 450 nm 
with 5 nm steps.7,8,10 The liposome alone emission spectra were recorded prior to adding the 
peptide stock and subtracted from each sample. The emission spectra of Hlys and AOA-Hlys 
samples (1.1 μL stock in 600 μL PBS, pH 8.0) were also recorded. 
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2.7.9 S. aureus Lipid Extraction 
A single S. aureus colony was selected from an LB agar plate and grown in LB media overnight at 
37°C with agitation. The next morning, the culture was diluted 100 times into fresh LB media and 
grown until an OD600 value between 0.5 and 0.6 was reached. The bacteria were pelleted via 
centrifugation at 5,000 rcf for 5 min, washed with PBS (pH 8.0) twice, and re-centrifuged. The 
bacteria were either treated with a small molecule (such as acetylation with 10 mM sulfo-NHS-
acetate, as described previously) or directly used for lipid extraction. To have enough bacteria for 
HPLC analysis, 7 mL of subculture at an OD600 value of 0.5 were used (~5 x 109 cfu/mL). 
Following the Bligh and Dyer method11, the bacteria pellet was resuspended in 0.8 mL of 0.12 M 
sodium acetate buffer, pH 4.8. Chloroform (1 mL) and methanol (2.2 mL) were added and the 
solution was vortex until homogeneous. The suspension was shaken at room temperature for 1 
hour, then centrifuged to pellet the cell debris. The supernatant was removed and put into a 
clean Falcon tube. Chloroform (1 mL) and deionized water (1 mL) were added and vortexed to 
mix well. The bottom chloroform layer was removed, placed into a clean glass vial and 
evaporated. The lipids were then either analyzed via TLC or fluorescein labeled then analyzed via 
analytical NP-HPLC. 
2.7.10 Lipid TLC Analysis 
Lipids dissolved in chloroform were spotted onto a silica gel 60 F254 TLC plates (Merck, Darmstadt, 
Germany) and developed in 65% chloroform : 30% methanol : 5% acetic acid until the solvent 
front was 1 mm from the top of the plate. The plates were stained with either ninhydrin or ceric 
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ammonium molybdate (CAM) and heated until spots became visible: purple spots with ninhydrin 
or dark blue spots with CAM. Lipid standards from Avanti Polar Lipids were spotted on each plate. 
2.7.11 Lipid Fluorescein Labeling 
10 mM 5/6-carboxyfluorescein succinimidyl ester (NHS-fluorescein) stock in DMF (5 μL) and 
triethylamine (1 μL) were added to lipids dissolved in chloroform (44 μL). The dark orange mixture 
was stirred at room temperature for 2 hours. To quench the remaining NHS-fluorescein, 30 mM 
ethylenediamine stock in chloroform (25 μL) was added and allowed to react for 5 mins until the 
solution was a fluorescent pink/yellow color. The crude reaction was directly analyzed via 
analytical NP-HPLC. 
2.7.12 Lipid Analytical HPLC Analysis 
Crude fluorescein-labeled lipids (10 μL) were injected onto an Atlantis HILIC Silica (3 μm 2.1 x 
150 mm) analytical column (Waters, Milford, MA). The flow rate was 0.3 mL/min throughout. 
Solvent A was 80% chloroform : 19.5% methanol : 0.5% ammonium hydroxide and Solvent B 
was 60% chloroform : 34% methanol : 5.5% water : 0.5% ammonium hydroxide. The gradient 
used was as follows: isocratic 100% A for 5 min, gradient from 0% to 85% over 30 min, gradient 
85% to 100% B over 2 min, isocratic 100% B for 5 min, gradient from 100% to 0% B over 5 min, 
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CHAPTER 3: 2-FORMYLPHENYLBORONIC ACID-BASED REVERSIBLE 




3.1 Reversible Bioorthogonal Chemistries 
As bioorthogonal chemistries continue to be discovered1,2, faster and more potent 
conjugations which do not require metal catalysts have become sought after. Reversible 
conjugation, especially covalent binding, is gaining increasing attention due to its high potency 
and selectivity. Reversible covalent chemistries have been utilized in dynamic combinatorial 
chemistry3, to design ligands that target biomolecules4, and as potential enzyme inhibitor drugs, 
which have decreased toxicity compared to irreversible covalent inhibitors.5 Specific reversible 
covalent conjugations include formation of boronate esters to target saccharides6–8, Michael 
addition of thiols to create covalent kinase inhibitors9,10, and modification of glutathione to 
generate specific sensors.11,12 
Our group and others have exploited the reactivity of amines to form iminoboronates 
through N-B dative bond stabilization when a 2-acetylphenylboronic (APBA) acid is used to bind 
proteins and lipids13,14 or promote peptide cyclization with an amine-containing residue.15,16 The 
potent reversible covalent interaction between APBA and amines has highlighted the utility of 
iminoboronate-stabilized conjugations as novel bioorthogonal reactions. 
 
3.2 Previous Work: Thiazolidino Boronate (TzB) Formation 
 Our lab and the Gois lab previously reported a novel conjugation chemistry between 2-
formylphenyl boronic acid (FPBA) and free cysteine (Cys) to form an iminoboronate-stabilized 
thiazolidine, named a thiazolidino boronate (TzB)17,18 (Scheme 3-1A). TzB complex formation is 
very potent (Kd = ~50 nM) and quick (t1/2 = 18 ± 2 sec) with a rate constant on the order of 103 M-
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1s-1, which is as fast as some of the quickest reported bioorthogonal reactions.19 The TzB complex 
between FPBA and Cys gives two characteristic 1H NMR shifts around 6.1 and 6.25 ppm, both 
representing the allylic hydrogen. There are two peaks because two TzB isomers form at neutral 
pH: the multicyclic mixed anhydride form and the open free carboxylic acid form (Figure 3-1A). 
 
3.3 Imidazolidino Boronate (IzB) Formation 
3.3.1 IzB Formation Between Dap and FPBA 
To explore other related conjugation chemistries, the reactivity of FPBA with the short 
chain lysine homolog 2,3-diaminopropionic acid (Dap) was explored. Dap is also a Cys analog, 
with a 1,2-diamino moiety instead of a 1,2-aminothiol moiety, allowing for similar types of 
reactivity. The FPBA-Dap conjugate, called an imidazolidino boronate (IzB), is structurally very 
similar to the TzB complex as an iminoboronate-stabilized imidazolidine (Scheme 3-1B). The rate 
constant was on the same order of magnitude as TzB formation (103 M-1s-1), however, the 
conjugate formation was less potent (Kd = ~100 μM), but slightly quicker (t1 = 6.2 ± 0.4 sec) than 
TzB formation (Figure 3-2). The IzB complex between FPBA and Dap also gives two characteristic 
1H NMR shifts around 5.7 and 5.8 ppm, representing the allylic hydrogen of the two IzB isomers 
(Figure 3-1B). 
Scheme 3-1: Comparison of 
previous thiazolidino 
boronate (TzB) conjugation to 
the current imidazolidino 
boronate (IzB) small molecule 
conjugation. X-ray crystal 
structures of both conjugates 






The crystal structure of the FPBA-Dap IzB was obtained at pH 7.4. The full structure was a 
tetramer of IzB complexes around a central NaCl molecule (Figure 3-3). The multicyclic monomer 
structure is highlighted in Scheme 3-1B. Structural data can be found in Table 3-1 and Table 3-2. 
B A Previous TzB Work Current IzB Work 
- 
Figure 3-1: Small molecule TzB and IzB Conjugate NMR Spectra. A) Previously reported 1H NMR of TzB 
formation between FPBA and Cys in neutral, aqueous solution, displaying the characteristic conjugate 
peaks around 6.1 and 6.25 ppm (green arrow).17 B) From this work, 1H NMR illustrating IzB formation 
as a function of pH, displaying two characteristic allylic H peaks around 5.7 and 5.8 ppm. Like TzB 
formation, there are two isomers seen at neutral pH, with the mixed anhydride assumed to be 
predominant at acidic pH values and the open free carboxylic acid isomer assumed to be predominant 
at basic pH values. Colored * correspond to the colored hydrogens. 
A B 
C 
Figure 3-2: Kinetics of IzB Formation 
Between FPBA and Dap. Reaction kinetics 
of IzB complex dissociation (A) and 
formation (B) with a t1 of about 6 seconds. 
Titration curve of IzB complex formation 
with increasing Dap concentrations (C). All 
monitored the appearance or 
disappearance of FPBA via UV-Vis 




Identification code  C40H44B4ClN8NaO12 
Empirical formula  C40 H44 B4 Cl N8 Na O12 
Formula weight  930.51 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Tetragonal 
Space group  I4 
Unit cell dimensions a = 17.4670(5) Å a= 90°. 
 b = 17.4670(5) Å b= 90°. 
 c = 6.7244(2) Å g = 90°. 
Volume 2051.59(13) Å3 
Z 2 
Density (calculated) 1.506 Mg/m3 
Absorption coefficient 1.580 mm-1 
F(000) 968 
Crystal size 0.250 x 0.220 x 0.140 mm3 
Theta range for data collection 5.064 to 66.529°. 
Index ranges -20<=h<=11, -20<=k<=19, -7<=l<=7 
Reflections collected 5002 
Independent reflections 1718 [R(int) = 0.0245] 
Completeness to theta = 66.529° 99.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.6716 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1718 / 1 / 163 
Goodness-of-fit on F2 1.039 
Final R indices [I>2sigma(I)] R1 = 0.0227, wR2 = 0.0577 
R indices (all data) R1 = 0.0232, wR2 = 0.0580 
Absolute structure parameter 0.032(8) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.305 and -0.156 e.Å-3 
______________________________________________________________________________ 
 
Table 3-1: Crystal data and structure refinement for the FPBA-Dap IzB complex. Structure Seen as a 




 x y z U(eq) 
______________________________________________________________________________ 
Na(1) 5000 5000 2511(3) 15(1) 
Cl(1) 5000 5000 6570(1) 14(1) 
O(1) 6341(1) 5315(1) 2576(2) 13(1) 
O(2) 7024(1) 5597(1) 5578(2) 13(1) 
O(3) 6905(1) 5644(1) 8865(2) 16(1) 
N(1) 6699(1) 4269(1) 5014(3) 12(1) 
N(2) 7501(1) 3290(1) 6337(3) 17(1) 
B(1) 6941(1) 5046(1) 3834(4) 12(1) 
C(1) 6914(1) 5280(1) 7325(3) 12(1) 
C(2) 6810(1) 4422(1) 7171(3) 14(1) 
C(3) 7529(1) 3942(1) 7708(4) 17(1) 
C(4) 7248(1) 3617(1) 4474(4) 15(1) 
C(5) 7877(1) 4011(1) 3306(3) 13(1) 
C(6) 8536(1) 3643(1) 2655(3) 16(1) 
C(7) 9065(1) 4057(1) 1550(4) 20(1) 
C(8) 8937(1) 4828(1) 1137(3) 18(1) 
C(9) 8280(1) 5192(1) 1808(3) 14(1) 
C(10) 7735(1) 4783(1) 2899(3) 12(1) 
______________________________________________________________________________ 
 
Table 3-2: Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x103) for 
the FPBA-Dap IzB complex. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Figure 3-3: Crystal structure of the tetrameric NaCl salt IzB complex between FPBA and Dap. 
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3.3.2 The Bioorthogonality of IzB Conjugation 
 The stability of the FPBA-Dap IzB complex towards biologically relevant moieties, such as 
amines (Lys), thiols (glutathione), diol boron chelators (glucose), 1,2-aminoalcohols (Ser), and 
1,2-aminothiols (Cys), was examined via 1H NMR (Figure 3-4). Glutathione, glucose, and Ser did 
not interfere with the IzB complex, so biological thiols, diol boron chelators, and 1,2-
aminoalcohols should not compete with IzB complexes. As expected, Cys at either an equimolar 
or 10-fold excess ratio to the IzB complex competed to form the TzB complex, as indicated by the 
disappearance of the two IzB peaks at 5.7 and 5.8 ppm (pink arrows) and the appearance of the 
TzB conjugate peaks at 6.1 and 6.25 ppm (green arrows). Lys caused slight competition via 
iminoboronate formation with the FPBA, as indicated by the appearance of an imine peak around 
8.4 ppm (blue asterisk). 
 
   
* 
Figure 3-4: Small Molecule 
Competition with Dap/FPBA IzB. 
1H NMR spectra of the IzB (1 mM) 
with a variety of potential 
biologically relevant small 
molecule inhibitors. Cys competed 
the IzB peaks around 5.7 and 5.8 
ppm (pink arrows) away to form a 
TzB conjugate, as indicated by the 
peaks around 6.1 and 6.25 ppm 
(green arrows). Lysine also caused 
minimal competition via 
iminoboronate formation with 
FPBA, forming an imine peak 
around 8.4 ppm (blue asterisk). Data obtained by Kaicheng Li 
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3.4 Attempts at TzB-Mediated Peptide Cyclization 
FPBA was previously shown to form a TzB with the N-terminal Cys of a short peptide, CAL, 
at neutral pH.17 To study intramolecular TzB formation, peptides containing an N-terminal Cys 
residue and a C-terminal FPBA-containing residue were synthesized in the hopes of using TzB 






3.4.1 Initial Peptide Synthetic Scheme 
In the first synthetic strategy, the orthogonal Alloc protecting group was selectively 
deprotected using palladium after Fmoc-based SPPS to reveal the free side chain amine of Dap 
at the C-terminus. A carboxylic acid derivative of FPBA was activated using HBTU and coupled to 
the Dap side chain amine under standard amide bond formation conditions. After on-resin Fmoc 
removal, the peptide was globally deprotected and cleaved from resin using a TFA and water 
mixture followed by HPLC purification. If an orthogonal protecting group was used on the side 
chain thiol of Cys, that would be selectively removed last and re-purified via HPLC (Scheme 3-2). 
Peptide Name Sequence 
CW1 CAAAAGDap(FPBA) 
CW2 SAAAAGDap(FPBA) 
CW3 CAVWAGDap(FPBA) – using Cys(Acm) 





Table 3-3: Peptide names and 
sequences used for TzB and IzB 





3.4.2 CW1 Peptide Synthesis 
First, the acid-labile Trt protecting group was used for the side chain thiol of Cys to make 
a short peptide containing an N-terminal Cys and a C-terminal FPBA-modified Dap residue: 
CAAAAGDap(FPBA), named CW1 (Table 3-3). After step 2, a small-scale acidic cleavage and 
peptide deprotection was performed to check peptide quality (Scheme 3-2). LCMS analysis of 
Fmoc-CW1 gave multiple peaks, corresponding to either peptide intermediates (Alloc-protected 
peptide and Alloc-deprotected but not FPBA coupled peptide) or the expected peptide mass 
minus one or two water molecules (Figure 3-5A). The presence of peptide intermediates 
indicated that the Alloc deprotection and FPBA coupling steps were not clean. The expected 
peptide mass minus one or more water molecules could be due to water loss from the boronic 
acid of FPBA, which has been reported before13,15. The peptide was not anticipated to be this 
Scheme 3-2: Initial N-terminal Cys and FPBA-containing peptide synthetic strategy. Used to make CW1 
through CW4 (CW1 shown). P.G. represents the Cys protecting group. 
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messy, as the N-terminal Fmoc protection should prevent TzB cyclization. After step 4, the 
deprotected peptide mass was not detectable via LC-MS. 
 
3.4.3 Serine Analog CW2 Peptide Synthesis 
 Given the messiness of CW1, the N-terminal serine (Ser) analog CW2 was made, which 
was not expected to react with FPBA, due to the high side chain pKa of Ser. This would allow us 
to examine the peptide synthetic strategy to ensure that FPBA could be cleanly incorporated into 
a peptide via Dap side chain modification. 
 After step 2, small scale acidic cleavage and LC-MS analysis gave only one peak, 
corresponding to the expected peptide mass of Fmoc-CW2 minus two water molecules (Figure 
3-5B). The water loss is most likely from the boronic acid, as the peptide was not expected to 
cyclize. After step 4, the expected mass of the deprotected peptide was readily seen via LC-MS. 
Therefore, the peptide synthesis was not the issue. 




      Fmoc-CW1             Fmoc-CW2            CW4 
(after -Fm & TCEP) 
Figure 3-5: Initial Peptide Synthesis 
Attempts. LC-MS trace after acidic 
cleavage and deprotection of the Trt-
protected Fmoc-CW1 peptide (A), 
displaying multiple peaks corresponding 
to intermediate peptides (in red) and the 
expected peptide mass minus one or 
two water molecules; the Fmoc-CW2 
peptide (B), displaying a single peak 
corresponding to the expected peptide 
mass minus two water molecules; and 
the CW4 peptide after Fm deprotection 
and TCEP reduction (C), displaying the 




3.4.4 CW3 and CW4 Peptide Synthesis 
The sequence was modified slightly to incorporate more hydrophobic residues, increasing 
the retention time on a reverse-phase HPLC column and allowing for easier LC-MS analysis. To 
keep the Cys side chain thiol protected during acidic cleavage, a few orthogonally protected Cys 
residues were explored. The acetamidomethyl (Acm) protecting group was initially used, but the 
Acm-protected CW3 peptide was difficult to purify after Fmoc deprotection. A variety of Acm 
deprotection conditions were used, including Hg(OAc)220, AgOAc21, AgOTf22, and PdCl2,23 of which 
AgOAc cleanly deprotected the Fmoc-Cys(Acm)-OH amino acid. After Acm deprotection with 
AgOAc, multiple peaks were seen for CW3 upon LC-MS analysis. Two peaks corresponded with 
the desired peptide mass minus two water molecules, but it was too messy to purify. 
Next, the 9-fluorenylmethyl (Fm) protecting group was chosen as its deprotection 
conditions (50% piperidine in DMF for 2h) were better tolerated. Fm-protected CW4 was 
synthesized and purified very cleanly. However, the LC-MS trace became messy upon Fm 
removal, although the dimer mass was seen. This was expected as the Fm deprotection 
conditions are known to given oxidized Cys thiols.24 HPLC purification did not yield a significantly 
more pure peptide. TCEP reduction did give the reduced monomer peptide mass, but made the 
LC-MS trace even messier (Figure 3-5C). 
 Overall, selective deprotection of the Cys residue did not yield cleanly or easily 
synthesized peptides. Those are essential to make a novel peptide cyclization strategy 
meaningful. Therefore, another strategy for incorporation of the FPBA moiety was investigated 
in attempts to create the N-terminal Cys and FPBA-containing peptide cleanly. 
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3.4.5 Modified Peptide Synthetic Scheme 
 The order of FPBA addition and Cys deprotection steps were reversed so that FPBA was 
added last to reduce possible side reactions. Instead of using a carboxylic acid FPBA derivative to 
amidate a Dap residue in DMF, an iodoacetamide FPBA derivative was used to alkylate a Cys 
residue in aqueous solution. The peptide was synthesized using standard Fmoc SPPS protocols 
and all acid-labile protecting groups, including an N-terminal Boc. After acidic resin cleavage and 
deprotection using Reagent K, the crude free peptide was dissolved in neutral PBS and reacted 
with FPBA for 5-10 minutes. This allows the N-terminal Cys to be protected as a TzB complex and 
not be available for alkylation with the iodoacetamide small molecule, which would react with 
any free thiol. After TzB protection, the iodoacetamide FPBA derivative is added and reacted 
overnight. The TzB complex is dissociated by acidifying the reaction before HPLC purification, 
yielding the free N-terminal Cys and FPBA modified peptide (Scheme 3-3). 
 
 
Scheme 3-3: Modified N-terminal Cys and FPBA-containing peptide synthetic strategy used to make 
CW5 and CW6 (CW5 shown). 
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3.4.6 CW5 Peptide Synthesis 
 After synthesis using the modified iodoacetamide method, CW5 was a single peak during 
HPLC purification but multiple peaks on the LC-MS trace, all corresponding to the expected 
peptide mass (linear) or the mass minus one (cyclic) or multiple water molecules (cyclic peptide 
with boronic acid water loss) (Figure 3-6B). Given that this peptide was the cleanest N-terminal 
Cys and FPBA-containing peptide made, the multiple peaks were determined to be due to an 
intrinsic intramolecular reactivity of an N-terminal Cys residue and FPBA. 
3.4.7 CW6 Peptide Synthesis 
 To examine a less reactive analogous peptide, an N-terminal Dap residue was used in 
place of Cys to induce IzB-mediated peptide cyclization (Figure 3-6A). IzB formation is less potent 
than TzB formation, so peptide cyclization was anticipated to be cleaner. After synthesis using 
the modified method and HPLC purification, CW6 gave a single peak on the HPLC and LC-MS 
trace, corresponding to the expected peptide mass (linear), the mass minus one water molecule 
(cyclic), and the mass minus two water molecules (cyclic peptide with boronic acid water loss) 
(Figure 3-6C). The single peak displaying the collection of masses related to the expected peptide 
mass indicated that there was one species present in multiple forms, whereas the multiple peaks 








3.5 IzB-Mediated Peptide Cyclization with KL21 and KL22 
3.5.1 KL21 and KL22 Peptide Synthesis 
Given the success of IzB-cyclized CW6, IzB-mediated peptide cyclization was further 
studied in a joint effort with Kaicheng Li. KL21 and KL22, N-terminal Dap and FPBA-containing 
peptides of various lengths, were synthesized using standard Fmoc-based SPPS and C-terminal 
Dap amidation method to install the FPBA moiety (Scheme 3-4). A simple sequence of alanine 
and glycine residues were used to simplify NMR analysis. Peptide synthesis with an N-terminal 
Dap residue was much easier than an N-terminal Cys residue and gave a clean peptide as seen 
via LC-MS (Figure 3-7). 





Figure 3-6: TzB- and IzB-Cyclized Peptides. Structures of liner and cyclic CW5 and CW6 (A). LC-MS 
traces of pure TzB-cyclized CW5 (B), displaying multiple peaks corresponding to the expected peptide 
mass minus one or two water molecules; and pure IzB-cyclized CW6 (C), displaying one peak of the 







3.5.2 pH-Dependent Peptide Cyclization 
Intramolecular IzB cyclization was examined via 1H NMR of KL21 and KL22 at various pH 
values in PBS buffer (Figure 3-8). Both peptides are completely linear at acidic pH (pH < 3), as 
indicated by the presence of the characteristic FPBA aldehyde peak around 9.8 ppm. Above pH 
5, the aldehyde peak begins to disappear and the IzB conjugate peak around 5.7 ppm appears. 
Lack of the aldehyde peak at neutral pH indicates complete cyclization of both peptides. 
Scheme 3-4: Synthetic route for KL21 and KL22 peptides (KL21 shown). 
B A 280 nm KL21 
Data obtained by Kaicheng Li 
Figure 3-7: LC UV trace (A) and mass spec data (B) of KL21. 
62 
 
Intramolecular cyclization results in one IzB conjugate peak because only one IzB isomer can 
form, as the amide bond of the N-terminal Dap residue prevents formation of the mixed 
anhydride isomer. 
Given their pH profiles, both KL21 and KL22 should be stable and remain cyclic under 
physiologic conditions. The pH-dependent reversibility of IzB cyclization would allow such cyclic 
peptides to act as “smart” peptides, able to become linear in slightly acidic environments, such 




KL21 KL22 B C 
Data obtained by Kaicheng Li 
Figure 3-8: pH-Dependent IzB Cyclization of KL21 and KL22 Peptides. Structures of IzB-cyclized KL21 
and KL22 peptides with the characteristic allylic H indicated in pink (A). 1H NMR spectra of KL21 (B) or 
KL22 (C) (500 μM) in buffer at increasing pH values. Cyclization is monitored via appearance of the IzB 




3.5.3 Stability of IzB-Cyclized KL21 Peptide 
 Due to the specific FPBA reactivity with either 1,2-aminothiol or 1,2-diamino moieties, no 
interference from other biologically relevant small molecules is expected. Cyclic KL21 at neutral 
pH was subjected to biologically relevant small molecules to probe intramolecular IzB stability 
towards amines (Lys), thiols (glutathione), diol boron chelators (glucose), and 1,2-aminoalcohols 
(Ser) (Figure 3-9). The IzB peak around 5.7 ppm persisted with all small molecule treatment, 
indicating IzB-cyclized peptides are stable to all the small molecules tested. 
 
 
3.6 Potential Application: Cysteine Sensing 
 Previously, TzB formation between FPBA and a short model peptide containing an N-
terminal Cys residue showed competition between free Cys and the peptide for TzB formation 
with FPBA.17 We also showed that the IzB complex between Dap and FPBA is in equilibrium with 
Data obtained by Kaicheng Li 
Figure 3-9: Biologically 
Relevant Small Molecule 
Competition with an IzB-
Cyclized Peptide. 1H NMR 
spectra of the KL21 
peptide (200 μM) with a 
variety of potential 
biologically relevant small 
molecule IzB inhibitors (2 
mM). None of the small 
molecules inhibited IzB 
formation, as indicated by 
the presence of the IzB 




the TzB complex upon addition of Cys. Therefore, it was hypothesized that an IzB-cyclized peptide 
could be linearized with Cys treatment (Scheme 3-5). Thus, an IzB-cyclized “smart” peptide could 
be used to respond to Cys, potentially acting as a Cys sensor. 
 
3.6.1 Cysteine Reactivity of IzB-Cyclized Peptides 
 The extent of Cys sensitivity of IzB-cyclized KL21 and KL22 was examined via 1H NMR. As 
expected, the TzB complex formed in a Cys concentration-dependent manner, as indicated by 
the appearance of the two IzB peaks around 6.1 and 6.25 ppm (green arrows) (Figure 3-10A, B). 
Linearization began around 0.3 mM and 2 mM Cys for KL21 and KL22, respectively. Upon plotting 
the integration of the TzB peaks compared to the IzB peak and curve fitting, EC50 values of 2.0 
mM and 1.5 mM for KL21 and KL22, respectively, could be determined (Figure 3-10C, D). 
 
Scheme 3-5: Cartoon depicting 
“smart” Cys-mediated peptide 
linearization via TzB formation. 
A B 




   
 
 
3.6.2 Cys-Dependent Linearization and Cys Oxidation of KL21 in FBS 
 To ensure the applicability of IzB-mediated peptide cyclization in biological applications, 
IzB-cyclized peptides must be stable in complex mixtures, such as a fetal bovine serum (FBS) 
solution. The cysteine sensing ability must also not be altered in the presence of a complex 
mixture. 
 Upon 1H NMR analysis, 10% FBS did not affect the cyclization of KL21 nor the ability of Cys 
linearize KL21 in a concentration-dependent manner (EC50 = 2.1 mM, Figure 3-11A). However, 
upon incubation at room temperature over 20 h, Cys oxidized to cystine, which could no longer 
form the TzB complex, as evident by the disappearance of the TzB peaks at 6.1 and 6.25 ppm. 
This allowed KL21 to re-cyclize, as seen by the re-appearance of the IzB benzylic peak around 5.8 
ppm (Figure 3-11B).  
EC50: 2.0 mM 
C KL21 
EC50: 1.5 mM 
KL22 D 
Figure 3-10: Cysteine Titration Competitions with IzB-Cyclized Peptides KL21 and KL22. 1H NMR 
spectra of cyclic KL21 (A) or cyclic KL22 (B) (200 μM) in neutral buffer with increasing Cys 
concentrations. Linearization is monitored via appearance of the two TzB isomer peaks around 6.0 and 
6.2 ppm (green arrows) and disappearance of the IzB peak around 5.8 ppm (pink arrow). Titration 









Data obtained by Kaicheng Li 
B 
Data obtained by Kaicheng Li 
Figure 3-11: Cysteine Responsiveness of IzB-Cyclized KL21 Peptide in FBS. (A) 1H NMR spectra of the 
Cys titration of KL21 (200 μM) in the presence of 10% FBS. There is no interference from FBS, as the 
IzB conjugate peak (pink arrow) becomes the TzB conjugate peaks (green arrows) with increasing Cys 
concentration. Integration of the TzB peaks relative to the IzB peak and curve fitting gave an EC50 
value for Cys-induced peptide linearization. (B) Time resolved 1H-NMR spectra measuring Cys 
oxidation in 10% FBS. As the Cys is oxidized over time, KL21 recyclizes, as indicated by the 
reappearance of the IzB peak. 
KL21 




 Inspired by our previously discovered reversible covalent TzB chemistry, TzB-cyclized 
peptides were pursued by incorporating an N-terminal Cys residue and C-terminal FPBA moiety. 
After multiple attempts using orthogonal Cys protecting groups and introduction of the FPBA at 
various synthetic steps, it was determined that intramolecular TzB formation yielded messy 
peptides for reasons yet to be understood. A few N-terminal Cys and FPBA-containing peptides 
were synthesized to give the expected masses via LC-MS analysis, but gave multiple peaks on the 
TIC trace corresponding to the correct mass or the mass minus one or multiple water molecules. 
Given the complications with TzB-mediated peptide cyclization, another related reversible 
covalent chemistry was characterized and explored. 
We have contributed a novel reversible covalent chemistry between Dap and FPBA to 
form an IzB complex. IzB conjugation is quickly reversible under physiological conditions and 
quite potent, with a Kd of approximately 100 μM. There is little interference from most 
biologically relevant small molecules, except Cys, which is known to readily form a TzB complex 
with FPBA. This conjugation can be utilized for rapid peptide cyclization at neutral pH, yielding a 
“smart” peptide that is able to linearize in both pH- and Cys-dependent manners. An IzB-cyclized 
peptide was also shown to be stable in the presence of FBS. Given the biocompatibility and 
chemoselectivity, IzB conjugation should be useful in the development of molecular probes and 
other “smart” materials. 
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3.8 Experimental Procedures 
3.8.1 General Methods 
Fmoc-Rink Amide MBHA resin and HBTU were purchased from Novabiochem (San Diego, CA). All 
Fmoc-protected amino acids and L-2,3-diaminopropionic acid (Dap) were purchased from either 
Chem-Impex International (Wood Dale, IL) or Advanced Chemtech (Louisville, KY). All other 
chemicals were purchased from Fisher Scientific (Pittsburgh, PA) or Sigma Aldrich (St. Louis, MO), 
unless otherwise indicated. IzB association and dissociation kinetics were studied using a 
NanoDrop 2000c UV-vis spectrometer. Peptide synthesis was carried out on a Tribute peptide 
synthesizer (Protein Technologies, Tucson, AZ). Peptide purification was performed on a Waters 
PrepLC system using a Phenomenex Jupiter C18 column (Torrance, CA). 1H NMR spectra were 
collected using a VNMRS 600 MHz NMR spectrometer with 256 scans at 25°C. NMR data were 
processed using MestReNova 11.0 software. Mass spectrometry data were collected using an 
Agilent 6230 LC TOF mass spectrometer. PBS buffer (1 mM) was used for all experiments. 
3.8.2 NMR Studies of FPBA Conjugation with Dap 
To prepare the IzB complex, 315 μL each of 22.2 mM FPBA and Dap stock solutions (in PBS) were 
mixed with 70 μL D2O (10 mM each final concentration, 10% D2O). The pH was tuned from 1 to 
10 incrementally. 
3.8.3 IzB Complex Crystallographic Information 
300 mM solutions of FPBA (22.5 mg in 500 μL) and Dap (21.1 mg in 500 μL) in water were 
prepared and combined. 1 mL of MeOH was added to that mixture and the pH was tuned to 7.4. 
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The solution was filtered through a 0.45 μm PTFE membrane filter (Phenomenex) and allowed to 
slowly evaporate from a loosely capped 5 mL glass vial at room temperature. After a few days, 
crystal aggregates were observed and redissolved in pure MeOH. After slow recrystallization at 
room temperature over a week, single crystals were observed. 
3.8.4 Kinetic and Thermodynamic Studies of the IzB Complex Formation 
Both the association and dissociation kinetics were examined via UV-vis absorption. The 
disappearance or appearance of the characteristic FPBA absorbance at 254 nm was used to 
measure the formation or breakdown of the IzB complex, respectively. Data were collected after 
blank subtraction using PBS (pH 7.4). The reactions were performed in a quartz cuvette (10 mm 
path length, total volume ~1 mL) using PBS at room temperature. All stock solutions were 
prepared in PBS (pH 7.4).  
For the dissociation reaction, an equimolar mixture of FPBA and Dap (1 mM) was created by 
mixing 90 μL of FPBA stock (10 mM) and 18 μL of Dap stock (50 mM) with 792 μL PBS. The mixture 
was incubated at room temperature for 15 minutes to allow the IzB complex to form completely. 
The mixture was diluted 16.7x to a final concentration of 60 μM and quickly mixed via pipetting. 
The absorbance profile was recorded approximately every 3 seconds. The initial absorbance 
value of the IzB complex was obtained from a separate equimolar mixture of FPBA and Dap (600 
μM) pre-incubated for 15 minutes. The absorbance at 254 nm was obtained via NanoDrop 
reading. A 600 μM solution measured using a 1 mm path length (NanoDrop) would be equivalent 
to a 60 μM solution measured using a 10-mm path length (cuvette). A rapid increase in 
absorbance at 254 nm was seen as FPBA was generated upon dissociation of the IzB complex. 
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Plotting the absorbance at 254 nm against time followed by curve fitting gave the relaxation time 
constant of the backward reaction. 
For the association reaction, 6 μL of FPBA stock (10 mM) was added to 994 μL PBS in the cuvette 
and mixed to make a 60 μM FPBA solution. The absorbance spectrum was recorded as the initial 
time point. 1.2 μL of Dap stock (50 mM) was added to the cuvette and quickly mixed via pipetting. 
The absorbance profile was recorded approximately every 3 seconds. A rapid decrease in 
absorbance at 254 nm was seen as the FPBA was converted to the IzB complex, which does not 
have an absorbance maximum at 254 nm. Plotting the time versus absorbance at 254 nm 
followed by curve fitting gave the forward reaction time constant. As the reactants were used at 
equal concentrations, the forward reaction kinetics data were fitted according to the equations 
of second order relaxation kinetics (details can be found on Page 369 of Physical Chemistry: 
Principles and Applications in Biological Sciences, Fourth Edition, by Tinoco et al., Prentice Hall 
PTR, 2001). 
For the equilibrium binding study, increasing amounts of a Dap stock (100 mM) was added to an 
FPBA solution (50 μM) to give final Dap concentrations of 100 μM to 900 μM. The decrease in 
absorbance at 254 nm was measured as the FPBA was converted to the IzB complex. Plotting the 
absorbance at 254 nm against the concentration of Dap gave the binding curve. Fitting the data 




3.8.5 Probing Small Molecule Interference of IzB Formation via NMR 
100 μL of FPBA-Dap IzB complex (10 mM) was diluted in 400 μL PBS (pH 7.4, 20% D2O). The 
solution was mixed with 500 μL stock solutions of lysine (20 mM), serine (20 mM), glutathione 
(20 mM), glucose (20 mM), and cysteine (2 mM) in phosphate buffer (Figure 3-3). The pH of the 
mixtures was tuned to 7.4. All samples were incubated for 30 minutes before the 1H-NMR spectra 
were taken. 
3.8.6 Peptide Synthesis and Characterization 
All peptides were synthesized using standard Fmoc-based SPPS on Rink Amide MBHA resin. They 
were carried out on a 0.05 mmol scale using 5 equivalents of each amino acid and 4.75 
equivalents of HBTU for each coupling reaction. 
CW1 through CW4 
Pd(PPh3)4 (100 mg) and phenylsilane (600μL) in DCM (2 mL) was added to the resin and stirred 
for 1-2 hours to selectively deprotect the Alloc group. A second Alloc removal was done if LCMS 
analysis shown incomplete deprotection upon small scale cleavage from resin. The FPBA 
functionality was installed by activating 4 (5 eq) with HBTU (4.7 eq) in 0.4 M NMM in DMF for 
about 5 minutes, then adding the solution to the peptide on-resin and mixing for 1-2 hours. The 
N-terminal Fmoc was deprotected with two 20% piperidine in DMF treatments for 5 min each. 
The peptide was cleaved off resin and globally deprotected with 95% trifluoroacetic acid : 5% 
water treatment for 2 hours. Cold ether precipitation yielded crude peptide, which was purified 
using RP-HPLC and lyophilized. For CW3 and CW4, the orthogonal Cys protecting group was 
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deprotected as described below. Peptide purity was assessed by LCMS. The calculated and 
observed m/z [M+H]+ values are listed below. 
Peptide Calculated [M+H]+ Observed [M+H]+ 
Fmoc-CW1 976.3677 958.3557 [M-H2O+H]+ 
Fmoc-CW2 960.3905 924.3701 [M-2H2O+H]+ 
C(Acm)-CW3 968.4102 968.4078 
CW3 897.3731 861.3520 [M-2H2O+H]+ 
C(Fm)-CW4 1075.4513 1075.4266 
CW4 897.3731 897.3767 
CW5 957.3765 939.3657 [M-H2O+H]+ 
CW6 940.4153 940.4138 
KL21 737.3384 737.3388 
KL22 865.3970 865.3965 
 
Acm Deprotection: Hg(OAc)2 & β-Mercaptoethanol20 
CW3 (5-10 mg/mL) was dissolved in 10% (v/v) aqueous acetic acid and the pH was adjusted to 3-
4. Hg(OAc)2 (10 eq) was added and the reaction was stirred under Ar at room temperature for 1 
hour. β-Mercaptoethanol (40 eq) was added and the reaction was allowed to sit at room 
temperature for 5 hours. The reaction was centrifuged to remove the Hg salts and the 
supernatant was analyzed for deprotection completion via LC-MS. 
Acm Deprotection: AgOAc & Dithiothreitol (DTT)21 
CW3(1 mg/mL) was dissolved in 1:1 acetic acid:water and AgOAc (35 eq) was added. The reaction 
was stirred at room temperature overnight. DTT (200 eq) added to the reaction and stirred for 
20 min at room temperature. The reaction was centrifuged to remove the Ag salts and the 
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supernatant was analyzed for deprotection completion via LC-MS. This was the cleanest and 
easiest to analyze deprotection condition. 
Acm Deprotection: AgOTf & DTT22 
CW3 (1 mg/mL) was dissolved in 99% TFA : 1% anisole and chilled over ice. AgOTf (100 eq) was 
added and the reaction was stirred on ice for 2 hours. After cold ether precipitation and 
centrifugation, the peptide-Ag salt was dried and dissolved in 1 M aqueous acetic acid (1 mg/mL). 
DTT (40 eq) was added and the reaction was stirred at room temperature for 3 hours. The 
reaction was centrifuged to remove the Ag salts and the supernatant was analyzed for 
deprotection completion via LC-MS. 
Acm Deprotection: PdCl2 & DTT23 
CW3 (2 mM) was dissolved in water and PdCl2 (10 eq) was added as a water solution. The reaction 
was incubated at 37°C for 50 minutes, then treated with DTT (20 eq) for 10-15 min at room 
temperature. The reaction was centrifuged to remove the Pd salts and the supernatant was 
analyzed for deprotection completion via LC-MS. 
Fm Deprotection24 
CW4 (1 mg) was dissolved in 50% piperidine in DMF (30 μL) and stirred at room temperature for 
2 hours. The crude peptide was directly RP-HPLC purified and LC-MS analysis revealed the peptide 
was oxidized. After lyophilization, CW4 (<0.5 mg) was dissolved in 95% water : 5% acetonitrile : 
0.1% TFA (10 μL). Excess TCEP was added and incubated at room temperature for 1 hour to 
reduce the peptide, then the solution was analyzed via LC-MS. 
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CW5 and CW6 
Directly after SPPS, the N-terminal Fmoc was deprotected with two 20% piperidine in DMF 
treatments for 5 min each. The peptide was cleaved off resin and globally deprotected with 85% 
TFA : 5% water : 5% phenol : 5% thioanisole for 2 hours. Cold ether precipitation yielded crude 
peptide, which was dried and immediately dissolved in PBS (1X, pH 7.4) and 95% water : 5% 
acetonitrile : 0.1% TFA (38% (v/v)) for peptide solubility. The FPBA moiety was installed through 
iodoacetamide reaction of an FPBA-iodoacetamide derivative with the C-terminal Cys side chain. 
FPBA (2 eq) was added to the crude peptide solution to form a complex with the N-terminal Cys 
or Dap residue, rendering it unreactive. The FPBA iodoacetamide derivative (1.5 eq) was added 
and the mixture was stirred overnight at room temperature. Acidification by adding TFA 
dissociated the FPBA from the N-terminal residue. The reaction was purified using RP-HPLC and 
peptide purity was assessed by LCMS. The calculated and observed m/z [M+H]+ values are listed 
above. 
KL21 and KL22 
Kaicheng Li performed the synthesis, purification, and most of the work involving KL21 and KL22. 
Pd(PPh3)4 (100 mg) and phenylsilane (600μL) in dichloromethane (2 mL) was added to the resin 
and stirred for 2 hours to selectively deprotect the Alloc group. The FPBA functionality was 
installed by activating 4 (4 eq) with HBTU (3.8 eq) in 0.4 M NMM in DMF for 5 min, then adding 
the solution to the peptide on-resin and mixing for 1h. After N-terminal Fmoc deprotection with 
20% piperidine in DMF, the peptide was cleaved off resin and globally deprotected with 85% TFA: 
5% water : 5% phenol : 5% thioanisole treatment for 2 hours. Cold ether precipitation yielded 
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crude peptide, which was purified using RP-HPLC and lyophilized. Peptide purity was assessed by 
1H NMR and LCMS. The calculated and observed m/z [M+H]+ values are listed above. 
For LCMS analysis, an Agilent Extend C18 (1.8 μm, 2.1 x 50 mm) analytical column was used with 
a water-acetonitrile mobile phase at a flow rate of 0.2 mL/min. The gradient used was as follows: 
isocratic 5% CH3CN for 5 min, gradient from 5% to 95% CH3CN in 10 min, isocratic 95% CH3CN for 
5 min, gradient from 95% to 5% CH3CN in 1 min, then isocratic 5% CH3CN for 5 min. 
3.8.7 pH-Dependent Cyclization of KL21 and KL22 
A solution of KL21 or KL22 (500 μM) in PBS (20% D2O) was prepared. The pH was tuned from 2.5 
to 7.4 incrementally. Cyclization was monitored by the disappearance of the FPBA aldehyde peak 
at 9.8 ppm and the appearance of the IzB benzylic hydrogen peak around 5.8 ppm. 
3.8.8 Probing Small Molecule Interference of Kl21 Cyclization via NMR 
KL21 (0.15 mg) was dissolved in 900 μL PBS (pH 7.4, 20% D2O, final KL21 concentration 200 μM). 
The solution was mixed with 100 μL stock solutions of lysine (20 mM), serine (20 mM), 
glutathione (20 mM), and glucose (20 mM) in PBS. The pH of the mixtures was tuned to 7.4. The 
samples were incubated for 30 minutes before the NMR spectra were taken. 
3.8.9 Cysteine-Induced KL21 Linearization 
KL21 (0.15 mg) or KL22 (0.18 mg) were dissolved in 800 μL PBS (pH 7.4, 20% D2O, final peptide 
concentration 200 μM). Increasing amounts of a cysteine stock (100 mM) in PBS was added to 
give final Cys concentrations of 100 μM to 4 mM. To ensure the Cys remained reduced, iTCEP (25 
μL) was added to the NMR tube. The pH of the mixture was tuned to 7.4. Titration curves were 
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generated by plotting the area of the two TzB benzylic proton peaks against Cys concentration. 
Fitting these titration curves using a hyperbolic equation gave the EC50 value for Cys-induced 
peptide linearization. 
3.8.10 Cysteine-Induced KL21 Linearization in Fetal Bovine Serum (FBS) 
To a solution of KL21 (200 μM) in 900 μL PBS (pH 7.4, 20% D2O) and 100 μL FBS (10% FBS (v/v)), 
increasing amounts of a Cys stock (100 mM) in phosphate buffer was added to give final Cys 
concentrations of 100 μM to 4 mM. To ensure the Cys remains reduced, iTCEP (25 μL) was added 
to the NMR tube. The pH of the mixtures was tuned to 7.4. All samples were incubated for 30 
minutes before the 1H-NMR spectra were taken. Titration curves were generated by plotting the 
area of the two TzB benzylic proton peaks against Cys concentration. Fitting these titration curves 
using a hyperbolic equation gave the EC50 value for Cys-induced peptide linearization. 
3.8.11 KL21 Cysteine Oxidation in FBS 
A solution of KL21 (200 μM) and Cys (4 mM) in 1.8 mL PBS (pH 7.4, 20% D2O) with 200 μL FBS 
(10% FBS (v/v)) was made and a 1H-NMR spectrum was recorded as soon as possible (~30 
minutes). The solution (~2 mL total volume) was incubated at 25°C in a scintillation vial open to 
air to allow gradual Cys oxidation over time. The 1H-NMR spectrum was recorded occasionally 
over the course of a few days. 
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3.8.12 Synthesis and Characterization of the Carboxylic Acid Derivative of FPBA (4) 
 
Synthesis of 1 
2,4-dihydroxylbenzaldehyde (3.00 g, 21.74 mmol) was dissolved in 10 mL acetone, to which tert-
butyl 2-bromoacetate (4.24 g, 21.43 mmol) and potassium carbonate (5 g, 36.23 mmol) was 
added. The reaction was stirred at 65 °C for 16 h then cooled down to room temperature. 150 
mL of water was added to the reaction mixture and extracted with ethyl acetate (3 x 150 mL). 
The organic layers were combined, washed with brine (150 mL) and dried over sodium sulfate. 
Ethyl acetate was evaporated, and the crude product was purified by silica column using ethyl 
acetate: hexane (1:10) to yield a white solid (2.90 g, 53%). 
1H-NMR (500 MHz, Chloroform-d) δ 11.42 (s, 1H), 9.72 (s, 1H), 7.44 (d, J = 8.7 Hz, 1H), 6.56 (d, J = 
11.1 Hz, 1H), 6.36 (d, J = 2.4 Hz, 1H), 4.55 (s, 2H), 1.48 (s, 9H). 
13C-NMR (126 MHz, Chloroform-d) δ 194.47, 166.81, 164.88, 164.25, 135.37, 115.70, 108.45, 
101.45, 82.97, 65.48, 28.00. 











Synthesis of 2 
1 (1.51 g, 6.00 mmol) and triethylamine (3.03 g, 30.00 mmol) were dissolved in 15 mL of 
dichloromethane and stirred at -78 °C for 5 min. Trifluoromethanesulfonic anhydride (3.39 g, 
12.00 mmol) was added slowly into the mixture over 1 min. The reaction was then allowed to stir 
at room temperature for 1 h under argon and quenched with 50 mL of saturated sodium 
bicarbonate. The mixture was stirred for 5 min and then extracted with dichloromethane (3 x 100 
mL). The combined organic layer was washed with brine (100 mL) and dried over sodium sulfate. 
After solvent removal, the crude product was purified by silica column using ethyl acetate: 
hexane (1:9) to yield a light yellow solid (1.90 g, 83%).  
1H-NMR (600 MHz, Chloroform-d) δ 10.13 (s, 1H), 7.94 (d, J = 8.7 Hz, 1H), 7.00 (dd, J = 8.7, 2.3 Hz, 
1H), 6.88 (d, J = 2.3 Hz, 1H), 4.61 (s, 2H), 1.49 (s, 9H). 
13C-NMR (151 MHz, Chloroform-d) δ 187.90, 168.90, 166.14, 153.79, 134.82, 125.08, 121.24, 
117.31, 111.52, 86.14, 68.56, 30.66. 







Synthesis of 3 
2 (1.50g, 3.90 mmol), B2pin2 (2.57g, 10.12 mmol), Pd(dppf)Cl2 (300 mg, 0.41 mmol) and potassium 
acetate (2.00 g, 21.01 mmol) were dissolved in 10 mL of anhydrous dioxane, to which ~100 mg 
of 3 Å molecular sieves were added. The reaction was flushed with argon for 15 min and allowed 
to stir for 1 h at 80 °C.  The reaction was cooled down to room temperature and water (50 mL) 
was added to the reaction. The product was extracted with ethyl acetate (3 x 100 mL). The 
combined organic layer was washed with brine (100 mL) and dried over sodium sulfate. Ethyl 
acetate was removed, and the product was purified on silica gel column using ethyl acetate: 
hexane (3:17) to give the desired product a white solid (0.54 g, 38% yield). 
1H-NMR (600 MHz, Chloroform-d) δ 10.40 (s, 1H), 7.93 (d, J = 8.6 Hz, 1H), 7.28 (d, J = 2.6 Hz, 1H), 
7.03 (dd, J = 8.6, 2.7 Hz, 1H), 4.59 (s, 2H), 1.48 (s, 9H), 1.37 (s, 12H). 
13C-NMR (151 MHz, Chloroform-d) δ 195.67, 169.89, 164.09, 138.03, 132.95, 123.06, 119.73, 
87.11, 85.40, 68.22, 30.65, 27.50. 









Synthesis of 4 
3 (200 mg, 0.55 mmol) was dissolved in 2 mL of dichloromethane and stirred at 0 °C, to which 3 
mL of trifluoroacetic acid (TFA) was added. The mixture was stirred at room temperature for 1 h 
before the dichloromethane and TFA were evaporated. The residue was treated with 5 mL of TFA 
for another hour at room temperature. Removing TFA completely via evaporation and washing 
with toluene and dichloromethane yielded an off-white powder as the desired product (150 mg, 
89%).  
1H NMR (600 MHz, DMSO-d6) δ 13.12 (s, 1H), 10.13 (s, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.16 – 7.10 
(m, 2H), 4.82 (s, 2H), 1.32 (s, 12H). 
13C NMR (151 MHz, DMSO-d6) δ 195.33, 172.74, 164.62, 137.18, 134.51, 123.14, 119.16, 87.21, 
67.67, 27.77. 
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS   
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4.1 Targeting S. aureus Membrane Amines 
 The aim of this research was to study the effects of S. aureus surface charge on 
antimicrobial susceptibility via peptide and small molecule manipulation. Previous studies 
utilized bacterial gene knockouts to alter the expression of cationic membrane modifications, 
such as Lys-PG. To the best of our knowledge, manipulating membrane charge to directly study 
the electrostatic influence of CAMP effectiveness has not been well characterized. 
 Co-treatment with Gramicidin A3R or Protegrin-1 and an iminoboronate-forming cyclic 
peptide caused increased S. aureus susceptibility to those CAMPs. The cyclic peptide, KAM-CT, is 
known to bind potently to S. aureus through iminoboronate formation between the 2-APBA 
moiety in the peptide and free amines on the bacterial surface. Occupying free amines in an 
iminoboronate eliminates their cationic charge at physiological pH, thereby decreasing the 
membrane surface charge. CAMPs are more electrostatically attracted to anionic membranes, 
leading to greater binding and more potent antimicrobial activity. 
Acetylating free surface amines achieved a similar effect by forming amides to quench 
the cationic amines. Treatment of S. aureus with sulfo-NHS-acetate followed by Gramicidin A3R 
and Protegrin-1 caused 2.5 or 10 times increase in S. aureus susceptibility to those CAMPs, 
respectively. 
 Nucleophilic cleavage of the lysine moiety of the Lys-PG headgroup to regenerate anionic 
PG was also explored. Initially, liposomes were treated with an esterase enzyme to selectively 
cleave the Lys-PG headgroup ester bond. However, no detectable lipids were extracted from the 
solution, so the experiment was inconclusive. 
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Next, non-specific small molecule nucleophiles were explored. Hydroxylamine was found 
to effectively cleave Lys-PG, by only at a 1 M concentration. As a more potent and specific 
cleavage moiety is desirable, the activity of the hydroxylamine-peptide conjugate AOA-Hlys was 
explored. The peptide, an antimicrobial fragment of human lysozyme called Hlys, would direct 
the hydroxylamine to the bacterial surface, where it should be in high enough concentration to 
effectively cleave Lys-PG, producing an anionic membrane. This was expected to increase CAMP 
activity based on a greater electrostatic interaction. Although AOA-Hlys did cause about 2-fold 
more Lys-PG cleavage in liposome models compared to hydroxylamine alone, it was less effective 
at killing S. aureus than the non-modified Hlys peptide. Binding of AOA-Hlys and Hlys to liposomes 
measured by Trp fluorescence was comparable. This indicates the importance of amphipathic 
balance in CAMPs – disrupting the amphipathicity by adding a hydrophilic moiety, such as 
hydroxylamine, might disrupt the propensity for membrane insertion, decreasing CAMP activity. 
 Interestingly, Hlys showed Lys-PG cleavage activity on its own in liposomes, which was 
not previously reported in literature. Quantification via ion intensity comparison using mass 
spectrometry (MS) is not typical, so NP-HPLC was used as a secondary analytical technique. After 
fluorescein labeling Lys-PG, the labeled lipid was quantified via fluorescein absorbance and 
compared to the remaining fluorescein as an internal standard. There appeared to be no 
significant difference in the Lys-PG amount extracted from untreated liposomes compared to 
liposomes treated with Hlys (100 μM). However, MS analysis showed twice as much Lys-PG 
cleavage in the presence of Hlys (100 μM) compared to untreated liposomes. Therefore, the Lys-
PG cleavage activity of Hlys could not be confirmed. 
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Lipid fluorescein labeling and NP-HPLC analysis was used to label and quantify Lys-PG 
extracted from wild type S. aureus and S. aureus treated with 10 mM sulfo-NHS-acetate. This 
method allows for quantification of Lys-PG extracted from bacteria. 
 
4.2 FPBA-Based Reversible Covalent Chemistries 
 Expanding the repertoire of reversible covalent chemistries, especially those applied to 
peptide cyclization, is desirable due to the high potency and selectivity of such interactions. Cyclic 
peptides are considered privileged scaffolds, displaying enhanced biostability and binding affinity 
than linear peptides. Cyclic peptides, such as KAM-CT, could be used as novel antibiotics or non-
lethal membrane modifiers. 
 Initially, TzB-cyclized peptides were pursued based on our previously characterized 
potent interaction of free Cys and 2-FPBA. However, synthesis of peptides containing an N-
terminal Cys residue and C-terminal residue functionalized with 2-FPBA proved difficult. The 
cleanest attempt gave multiple TIC peaks upon LC-MS analysis, all corresponding to the expected 
peptide mass or the peptide mass minus one or two water molecules. Seeing the peptide mass 
minus one or two water molecules would be expected due to a loss of water upon peptide 
cyclization and the known phenomena of boronic acids losing water during MS analysis. 
However, why the peptide gave multiple peaks with the same mass is yet to be understood. 
 Next, we explored the reactivity of moieties similar to the 1,2 aminothiol functionality in 
Cys. The Dap residue bears a 1,2-diamino moiety and it was found to form a similar complex with 
2-FPBA, called IzB. IzB conjugation is potent (Kd = 100 μM) and quickly reversible under 
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physiological conditions. With little interference from reactive biologically relevant small 
molecules, except Cys, IzB formation was successfully utilized as a reversible covalent peptide 
cyclization strategy. 
 Cys interference of IzB conjugation was utilized to create “smart” peptides, which can 
linearize in response to both acidic pH and Cys concentration. Such peptides were found to be 
both stable and able to report on the Cys concentration in a FBS solution. 
 
4.3 Future Directions 
 Further establishing the fluorescein labeling and HPLC analysis protocol by repeating 
literature findings would be advantageous. Ultimately, Lys-PG extracted from bacteria could be 
analyzed after treatment with various agents, such as antimicrobial peptides or Lys-PG cleavage 
inducing molecules. 
 
